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Abstract 
The phosphatase and tensin homolog deleted on chromosome 10, (PTEN) gene encodes a 
tumor suppressor phosphatase frequently mutated in various human cancers. Somatic missense 
mutations of PTEN have recently been found in patients with endometriosis, endometrial cancer, 
and ovarian cancer. Here we present the first computational analysis of 13 somatic missense 
PTEN mutations to assess a possible genotype-phenotype correlation in endometriosis and 
cancer. We posit PTEN’s active site defines a possible mutation-driven allosteric region wherein 
a subset of mutations correlate with endometriosis, endometrial cancer, and ovarian cancer. Our 
data suggest that mutations within the active site disrupt the structural stability, electrostatic 
interaction, global dynamics and the structural communication pathway, likely contributing to the 
aforementioned phenotypes.  
Multiple in silico prediction methods were utilized to calculate protein structural stability 
changes produced by each mutation; decreases in protein structure stability were seen in each 
mutation with an increase in dynamics across the phosphatase-C2 domain interface of 
R130G/L/Q and R173C/H mutations. To assess the impact on intrinsic and global dynamics, 
elastic network models (ENMs) were employed demonstrating changes from wild-type “hinge-
bending” to “zipper-like” global motions induced by each mutation. All-atom molecular 
dynamics (MD) simulations revealed large conformational changes that affect the global 
dynamics of the active site loops and the CBR3 loop in the C2 domain. Interestingly, mutations 
G36E/R, C124S, G129R, R130L/Q, R173C/H, and V191A dramatically affected the principal 
motions of the active site loops and inter-domain interface.  Overall, the global dynamics induced 
by each mutation effects reveal unique long-range perturbations that may impair PTEN’s 
function. 
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We further investigated structural communication within each mutant system using 
protein structure network (PSN) analysis and found that R130 and R173 play critical roles in 
controlling salient communication pathways suggesting a compelling interplay between the two 
positions involving a potential mutation-driven allosteric interface. The results of this research 
provide a greater understanding of the mechanistic role of mutated PTEN associated with 
endometriosis and cancer. It is our hope that these results will aid in a better clinical-molecular 
classification of the resulting phenotypes allowing for translation into improved diagnostic and 
therapeutic approaches. 
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Chapter 1: Introduction 
1.1 Phosphatase and tensin homolog deleted on chromosome 
ten, (PTEN) 
1.1.1 PTEN-PI3K signaling 
Originally discovered in 1997, the PTEN (phosphatase and tensin homolog deleted on 
chromosome 10) tumor suppressor also referred to as MMAC (mutated in multiple advanced 
cancers) and TEP-1 (TGF-β-regulated and epithelial cell enriched phosphatase) was the first 
phosphatase identified to be frequently mutated/deleted in various human cancers.1-3 The PTEN 
gene, located at 10q23.3, encodes a 403-amino acid dual-specificity phosphatase having both 
protein and lipid phosphatase activity.4 As a protein phosphatase, PTEN exerts its function by 
dephosphorylating tyrosine-, threonine-, and serine-, phosphorylated proteins thus regulating the 
cell cycle and proliferation.4 However, its most relevant function is based in its ability to catalyze 
the dephosphorylation of the 3’ phosphate of the inositol ring in phosphatidylinositol (3,4,5)-
triphosphate (PIP3), an important intracellular lipid second messenger, with greater alacrity, thus 
lowering it’s level within the cell.5  
In dephosphorylating PIP3 to produce phosphatidylinositol (4,5)-bisphosphate (PIP2), 
PTEN negatively regulates the upstream phosphotidylinositol 3-kinase (PI3K)/Akt pathway thus 
restraining downstream anti-apoptotic and growth stimulatory effects of PDK1 
(phosphoinositide-dependent kinase) and protein kinase B (PKB/Akt) that promote cellular 
proliferation and survival.4,6 The PI3K/Akt pathway is a major survival pathway activated in 
cancer with PTEN constituting the main node of inhibition by limiting the phosphorylation and 
activation of Akt, thereby regulating progression of the cell cycle and induction of apoptosis.7 
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Hence, the molecular mechanisms attributed to PTEN are consistent with its role as a tumor 
suppressor.  
 
Figure 1.1 PTEN-PI3K-AKT signaling pathway 
 
 
 
1.1.2 PTEN structure 
  The human PTEN protein consists of 403 amino acid residues with multiple domains 
that contribute to its function and stability which include: (i) phosphatidylinositol 4,5-
bisphosphate – binding motif (residues 6-15), (ii) N-terminal phosphatase domain (residues 15-
185), (iii) C2 domain (residues 185-351), (iv) C-terminal tail (residues 352-400), (v) two PEST 
motifs (residues 350-375 and 379-386), (vi) PDZ-binding domain (residues 401-403), (vii) and 
two ATP-binding motifs (residues 60-73 and 122-136).4,8-12  
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Figure 1.2 PTEN domain structure 
 
The full length PTEN protein, however was not amenable to crystallization, and 
proteolytic digestion of N-terminal residues 1-13, internal D-loop (residues 286-309), and C-tail 
(residues 353-403) revealed these regions as loosely folded or unstructured, thus, identifying 
PTEN as an intrinsically disordered protein (IDP).4,13 The functional versatility of PTEN is 
attributed to its IDP regions which allow it to interact with over 400 proteins in different 
subcellular compartments such as plasma membrane, cytoplasm, nucleus, and exosomes.14 
However, recombinant PTEN lacking unstructured regions resulted in the crystallization of PTEN 
(PDB ID 1D5R) which include only the phosphatase domain (residues 15-185), that 
accommodates the invariant signature motif HCXXGXXR (commonly abbreviated C(x)5R) and a 
tightly associated C2 domain (residues 186-351) which participates in membrane binding.4  
 
Figure 1.3 PTEN three-dimensional structure 
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The phosphatase domain contains a central five-stranded β-sheet with six α-helices (two 
α-helices on one side and four on the other).  Similar to other protein tyrosine phosphatases 
(PTPs) and dual-specificity phosphatases (DSPs), PTEN has two α-helix motifs that flank the 
catalytic active site that consist of: (i) α1-helix (residues 48-59) and (ii) α6-helix (residues 161-
177).15,16 Though not directly involved in catalysis, the α1-helix assists with the formation of the 
overall secondary structure.15,16 The C2 domain represents a β–sandwich that consists of two 
antiparallel β-sheets with two short α–helices intervening between the strands and three CBR3, 
Cα2, and Cβ1/2 loops located on the membrane facing surface. The C2 domain bears hallmarks 
of Ca2+-dependent phosphatases, however, it lacks the essential Asp-268, a Ca2+ ligand and 
therefore binds to membranes in a Ca2+ -independent manner.4 
The phosphatase and C2 domains associate across an extensive interface that is adjacent 
to the active-site and consists of conserved residues frequently mutated in cancer.4 The 
interactions of these two domains are controlled by three loops located in the catalytic active-site 
pocket. The wall of this pocket is delimited in part by the WPD loop (residues 88-98), the 
signature motif P loop (H123CKAGKGR130), and TI loop (residues 160-171) which contain 
residues that are responsible for catalysis (D92, C124, and R130), the overall positive charge 
within the active-site (H93, K125, K128), mediation of loop motion (H123 and G127), and 
govern the depth and width of pocket (4-residue insertion K163, K164, G165, V166).4 The 
phosphatase domain shares homology with both tensin and auxilin proteins and contains two 
signature motifs: (i) the phosphate binding loop (P loop) HCXXGXXR and (ii) the “Trp-Pro-
Asp” loop (WPD loop) commonly found in the regulatory sites of PTPs and DSPs (Figure 1.4).  
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Figure 1.4 PTEN signature motif alignment 
 
Adapted from Maehama and Dixon 199917 
 
The phosphatase domain however contains a rather wide and deep catalytic pocket 
specific only to PTEN. In fact, the architecture of the active-site of PTEN is sufficiently large 
enough to accommodate the sugar head group of inositol phospholipids as a substrate allowing 
for catalytic specificity.4,17-19 The active-site pocket of PTEN is ~8 Å deep with an elliptical 
opening of ~5 x 11 Å.4 The extension and larger width of the active-site pocket is due to the four-
residue insertion of the TI loop (Figure 1.5). The P loop contains residues K125 and K128 at its 
center, which along with H93 of the WPD loop imparts a highly positive charge to the pocket 
leading to the preference of negatively charged PI(3,4,5)P3 and highly acidic polypeptide 
substrates.4 The pocket extension and highly positive charge of said pocket coupled together set 
PTEN apart from other phosphatases. Mutations in the TI loop (T167), WPD loop (H93 and 
D92), and P loop (C124, K128, G129, and R130) lead to a reduction in PIP3 phosphatase activity 
by ~75%.4  
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Figure 1.5  PTEN-PIP3 structure 
 !
1.1.3 Mechanism of action 
Figure 1.6 PTEN catalytic mechanism  
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Adapted from Zhang20 and Tautz21  
 
As a dual-specificity phosphatase, PTEN can dephosphorylate both Ser/Thr/Tyr protein 
substrates as well as phospholipids substrates. The mechanism determining whether PTEN acts as 
a protein or lipid phosphatase remains unclear. However, PTEN is highly selective for the lipid 
second messenger, PIP3 and catalyzes its dephosphorylation via a two-step mechanism: (i) 
through the transfer of the target phosphate moiety from the substrate to the conserved cysteine 
forming a cysteinyl phosphoenzyme intermediate, and (ii) hydrolysis of the phosphoenzyme 
intermediate to form inorganic phosphate.     
Specifically, the P loop contains both the catalytically conserved cysteine at position 124, 
which forms a cysteinyl phosphoenzyme intermediate that is subsequently hydrolyzed, and 
arginine 130, which binds to the D3-phosphate of PIP3 transferring it to C124. In step 1, the 
catalytic cysteine, located at the base of the active-site cleft, acts as a nucleophile by attacking the 
phosphorous atom in the phosphate moiety of PIP3 resulting in the formation of a thiol phosphate 
intermediate.22,23 Arginine 130 plays a crucial role in the binding of the phosphoryl group 
contributing to transition-state stabilization,! 23-25 while D92, a general acid of the WPD loop, 
donates a proton to the substrate-leaving group. In step 2, D92 now serves as a general base by 
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abstracting a proton from a water molecule. The cysteinyl phosphoenzyme intermediate is then 
hydrolyzed resulting in the liberation of the PO3 moiety and enzyme regeneration.20,25,26 The 
conserved residues histidine 123 and threonine 131, assist in regulating both the pKa of C124 as 
well as in facilitating hydrolysis.25 
The conserved aspartic acid 92 (~30-40 residues away from catalytic cysteine) in the 
WPD loop acts both as a general acid and general base, respectfully, in step 1 and step 2 of the 
dephosphorylation mechanism.27 Moreover, the WPD loop may undergo rapid movement upon 
substrate binding allowing for optimal positioning of D92 for catalysis.27,28 The WPD loop is 
designated in the “open” state prior to substrate binding to the P loop signature motif where it is 
oriented away from the active-site.29 Upon substrate binding, the WPD loop moves toward the 
catalytic pocket, bringing D92 in close proximity to the substrate.29 This conformation is 
designated as the WPD loop “closed state”. Dephosphorylation of phospholipid substrates and 
phosphopeptide substrates reveal a pronounced difference in the role of D92 in the 
dephosphorylation of the two types of substrates.27 In fact, phospholipid substrates and not 
phosphopeptide substrates are able to recruit the WPD loop into the active-site such that D92 can 
participate in catalysis. Previous studies of the recombinant PTEN in complex with tartrate, 
which mimics the phosphorylated inositol ring of PIP3 (PDB ID 1D5R), illustrates the WPD loop 
adopts the “closed” conformation.27 It is posited that the WPD loop is recruited to the active-site 
by way of H93 via interaction with the D5 phosphate of PIP3.4 
 
1.2 Endometriosis 
1.2.1 Overview and definition 
Endometriosis is a chronic estrogen-dependent inflammatory disease defined as the 
presence of endometrial tissue outside (ectopic) the uterine cavity in various areas throughout the 
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body developing into lesions, adhesions, implants, or tumors resulting in severe dysmenorrhea 
(painful menses), dyspareunia (painful intercourse), dysuria (painful urination), dyschezia 
(defecation difficulties), chronic fatigue, frequent miscarriages, and infertility.30-34 Ectopic 
endometrial tissue (uterine womb lining) located within the muscle wall of the uterus is called 
endometriosis interna or adenomyosis. The extent of endometriosis varies from small red, 
blue/black, or white lesions on the outer surface of the pelvis, peritoneum or pelvic organs to 
large ovarian endometriotic cysts (endometriomas) that invade the ovaries.35 This displaced 
endometrial tissue responds to hormonal changes during menses resulting in irritation and internal 
bleeding which produces extensive fibrosis and internal scar tissue known as adhesions that 
spread out across pelvic organs, binding them together, leading to distortion of the pelvic 
anatomy. Occasionally, endometriosis can be found on the kidneys, bladder, diaphragm, liver, 
nerves, ureter, bowel, walls of intestine, in tissue between the vagina, and rectum, and even the 
brain.35-46  
 
1.2.2 Statistics 
Endometriosis affects an estimated 176 million women worldwide showing no disparity 
towards age, ethnicity, or social circumstances.47 With an estimated frequency of 5%-10% among 
women of reproductive age31,33,34, endometriosis is the third leading cause of gynecologic 
hospitalization in developed countries and a leading cause of hysterectomy.31 The prevalence rate 
of pelvic endometriosis approaches 6-10% in the general female population; in women with pain, 
infertility, or both, the frequency is 35%-50%.33   
 
1.2.3 Pathogenesis 
Though the exact pathogenesis and etiology of endometriosis has yet to be elucidated, 
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there are several mechanistic theories as to how the endometrial tissue escapes the uterine cavity 
and implants itself onto organs of the pelvic cavity (Table 1.1). Leading theories include: (1) 
Sampson’s theory – retrograde menstrual reflux through the fallopian tubes into peritoneal 
cavity,48 (2) Metaplastic theory – conversion of coelomic epithelium into various types of 
tissue,48 (3) Embryonic rest müllerianosis theory – remnant müllerian cells that remained in 
pelvic tissue during development of the Müllerian system. Under estrogen stimulation, residual 
cells from embryologic müllerian duct migration may be induced into functioning endometrial 
glands and stroma.48 (4) Benign metastasis theory – ectopic endometrial implants are the result of 
lymphatic or hematogenous dissemination of endometrial cells into the venous circulation.49,50 
However, more recently, it has been accepted that endometriosis has a multifactorial etiology 
which include genetic, hormonal, and environmental factors.33,48,51 
Sampson’s theory is the oldest and most accepted theory explaining the etiology of 
endometriosis. This theory suggests that endometriosis occurs as a result of the retrograde flow of 
sloughed endometrial cells/debris via the fallopian tubes into the pelvic cavity during 
menstruation.52 However, retrograde menstruation through the fallopian tubes occurs in 70-90% 
of women and not all of these women develop endometriosis.53 Yet, patients that develop 
endometriosis have a larger volume of retrograde menstrual fluid found in their pelvises 
compared to healthy women, which may increase the risk of endometriotic lesion implantation.54  
Metaplastic theory may explain the occurrence of endometriosis in pre-pubertal girls.55 
Metaplasia of the coelomic epithelium involves the transformation of normal peritoneal tissue to 
ectopic endometrial tissue induced possibly by environmental factors that promote the 
differentiation of cells resulting in the formation of endometrial cells and endometriomas.33,56 
However, the driving force for endometrial growth, estrogen, is absent in pre-pubertal girls, and 
therefore the genesis of endometriosis may be different in women of reproductive age.55 The fact 
that ectopic endometrial tissue has been detected in female fetuses as well as in men, suggests 
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that endometriosis may be the result of defective embryogenesis.57,58  
The Embryonic rest müllerianosis theory best explains the implication of endometriotic 
lesion development under the influence of estrogen or estrogen mimetics. According to this 
theory, residual Müllerian or Wolffian ducts grow caudally, fuse with the urogenital sinus of the 
pelvis, and develop into endometriotic lesions that respond to estrogen.56 Benign metastasis 
postulates that endometrial cells gain entry into open basal lymph and blood vessels and are 
embolized to ectopic sites. The growth of endometriotic lesions could theoretically seed 
additional lesions in the pelvic cavity and other distal sites.59   
More than 20 years ago heritable genetic factors were recognized when the risk for first-
degree relatives of women with severe endometriosis were reported to be six times higher than 
that for relatives of unaffected women.60-63 In fact, familial aggregation has been shown in twin 
studies64-66 and in clinical60,67 and population-based68 samples. Additionally, various groups have 
reported candidate genes that have potential biological susceptibility to endometriosis by the 
utilization of linkage analysis and affected sibling pairs (Table 1.2),69-76 this includes genes 
associated with malignant transformation (PTEN, p53, estrogen-, progesterone-, and androgen- 
receptors).76-79  
Since endometriosis is an estrogen-driven disease, the role of steroid hormones plays a 
central role in the pathogenesis of endometriosis. Similar to the eutopic (normal) endometrium, 
endometrial proliferation, and the growth of ectopic lesions have an increased response to 
estrogen thus enhancing the progression of endometriosis.80 Moreover, endometriotic tissue 
relative to eutopic endometrium exhibits an increased expression of the aromatase enzyme and 
decreased expression of 17β-hydroxysteroid dehydrogenase (17β-HSD type 2).81 Aromatase gives 
rise to local biosynthesis of estradiol thereby stimulating production of prostaglandin E2 and 
establishing a positive feedback cycle.81,82 Prostaglandin E2 further stimulates activity of 
aromatase favoring the accumulation of estrogen and prostaglandins. Thus, estradiol synthesis is 
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increased while its inactivation is decreased, resulting in higher concentrations of the hormone 
and increased proliferation of endometriosis.  
The increasing incidence of endometriosis as well as higher prevalence rates of severe 
endometriosis in industrialized countries suggests a possible link between endometriosis and 
environmental factors. However, to date, there has been no large-scale epidemiological study 
definitively linking a particular class of chemicals to the risk of endometriosis.33 Although 
estrogen-like compounds,83 endocrine disruptors,84 and the environmental toxin dioxin85 have 
been suggested as possible factors, the developmental timing of action of such agents and their 
roles in influencing other systems that predispose endometriosis must be considered in the 
context of genetic background as well as stimulus-driven reprogramming of the female 
reproductive tract.56 
 
Table 1.1 Theories on the pathogenesis of endometriosis 
Theory Explanation 
Mechanistic Theories 
(1) Sampson’s theory – retrograde 
implantation  
Endometrial tissue sloughed through fallopian 
tubes into peritoneal cavity 
(2) Metaplastic theory – coelomic 
metaplasia 
Extrauterine cells that abnormally differentiate 
into endometrial cells 
(3) Embryonic rest müllerianosis theory Remnant müllerian cells that may be induced 
into endometrial glands and stroma under 
estrogen stimulation 
(4) Benign Metastasis theory  Lymphatic and vascular dissemination of 
endometrial cells 
Multifactorial Etiologies 
(5) Genetic basis  Alteration of cellular function that increases the 
attachment of ectopic endometrial cells to the 
peritoneal epithelium 
(6) Hormonal basis Estrogen-driven proliferation of endometrial 
lesions 
(7) Environmental basis  Exposure to toxic chemicals (i.e. dioxins, PCBs) 
and endocrine disrupting chemicals 
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Table 1.2 Candidate genes and susceptibility to endometriosis 
Gene Chromosomal locus 
Steroid Enzymes and Hormone Receptors   
Cytochrome P450 1A1 (CYP1A1) 15q24 
Progesterone Receptor (PGR) 11q22-23 
Androgen Receptor (AR) Xq12 
Hydroxysteroid (17-β) dehydrogenase 1 (HSD17β1) 17q11-21 
PPARγ2 Pro-12-Ala allele 3q25 
Estrogen Receptor  
ERα (ER1) 
ERβ (ER2) 
 
6q24-27 
14q21-22 
Xenobiotic Metabolism  
N-acetyl Transferase 2 8p22 
Glutathione-M-Transferase 1 (GSTM1) 1p13.3 
Glutathione-S-Transferase 1 (GSTT1) 22q11.2 
Signal Transduction  
Phosphatase and Tensin Homolog deleted on chromosome ten (PTEN) 10q23 
Kirsten Rat Sarcoma viral oncogene homolog (KRAS) 12p12 
Tumor Suppressor - TP53 (p53) 17p13 
Adhesion and Inflammation Molecules  
Interleukin adhesion molecule (ICAM1) 19p13 
Tumor Necrosis Factor-α (TNFα) 6p21.3 
Vascular Endothelial Growth Factor (VEGFA) 6p21-12 
Glutathione-1-phosphate uridyl Transferase (GALT) 9p13 
Transcription Factor  
Empty Spiracles Homeobox 2 (EMX2) 10q26.1 
 
1.2.4 Diagnosis 
Establishing a diagnosis of endometriosis can be quite challenging with the time between 
onset of symptoms and a definitive diagnosis in most cases taking several years. In fact, the 
average delay of diagnosis is approximately 7-12 years.86-91 Non-invasive techniques have been 
utilized to detect endometriosis namely, magnetic resonance imaging (MRI),92 computed 
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tomography scans,93  ultrasound,94-99 and transvaginal hydrolaparoscopy100 as well as the use of 
serum and peritoneal fluid biomarkers such as cancer antigen 125 (CA-125),101,102 cytokines 
Interleukin-6 (IL-6),103 and tumor necrosis factor-alpha (TNF-α).103 However, further 
investigation is needed to evaluate the relevance and validity of these non-invasive techniques for 
diagnosis, as these modalities are not helpful in assessing the severity and invasiveness of 
endometriosis on a case by case basis. 
A definitive diagnosis can only be made by means of surgical laparoscopy which is 
considered the gold standard and primary diagnostic modality for endometriosis. Furthermore, the 
severity of endometriosis is determined by the American Society of Reproductive Medicine 
(ASRM) classification system which quantifies disease by a point system into one of four stages 
(Table 1.3): minimal disease (stage I), mild disease (stage II), moderate disease (stage III), and 
severe disease (stage IV).104 Through laparoscopic visual observations, disease severity is 
classified based on location, depth of invasion, extent of endometriosis implants, severity of 
adhesions, and presence/size of ovarian endometriomas.  
 
Table 1.3 Stages of endometriosis 
Stage Level of Severity Description Total Points 
I Minimal Presentation of 2-3 brownish, reddish, blue-
black, white or clear superficial implants 
4 
II Mild Appearance of more implants that occur 
within deeper layers of tissue 
9 
III Moderate Many deep implants in combination with 
minor/small endometriomas on one or both 
ovaries. May have chocolate cysts and filmy 
adhesions 
26-30 
IV Severe Persistence of deep implants, enlargement of 
endometriomas on one or both ovaries, 
development of dense adhesions. Presence of 
chocolate cysts. Reproductive organs are 
bound down by growths, bladder, and/or 
bowel may also be affected 
52-114 
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1.2.5 Treatment 
Although there is currently no known cure, hormonal and surgical options are available to 
manage symptoms associated with the disease. Endometriosis progresses and represses in an 
estrogen-dependent fashion; therefore hormonal-medical treatment provides the basis for 
therapeutic interventions. Hormonal treatment with a combination of oral contraceptive pills 
(OCPs), progestins, gonadotropin-releasing hormones (GnRH) analogues, danazol, and the 
levonorgestrel-releasing intrauterine system (lng-IUS) is warranted to repress growth and 
proliferation of endometriotic lesions and alleviate pain. Yet treatment with lng-IUS, only 
alleviates pain and does not affect repression of disease.105 Aromatase inhibitors either alone or in 
combination with oral contraceptives are also beneficial in reducing pain symptoms.81,106-108 Non-
steroidal anti-inflammatory drugs (NSAIDs) are also widely utilized to treat chronic pain 
associated with endometriosis. However, sometimes more powerful medications like opioids are 
needed. Additional pain options include acupuncture, physiotherapy, and the use of 
transcutaneous electrical nerve stimulations (TENS). 
Surgical treatment for endometriosis involves the excision of endometriotic lesions, 
cysts, and fibrotic adhesions lowering the inflammatory response, reducing pain and improving 
fertility. Surgical treatment is broadly classified as conservative (excision of cysts, endometriotic 
lesions, and adhesions), semiconservative (removal of uterus, cervix, and one or more ovaries) 
and radical (removal of uterus, cervix, fallopian tubes, ovaries, and vagina).109 In addition to 
excision surgery, a pre-sacral neurectomy (PSN), endometrial ablation, or laparoscopic uterine 
nerve ablation (LUNA) can be performed to aid in pain management.110,111 Definitive surgery 
which includes hysterectomy and removal of ovaries is reserved for women with intractable pain 
or who no longer desire pregnancy.112 However, a high recurrence rate of 62% has been reported 
in advanced stages of endometriosis, in which ovaries were conserved after hysterectomy.112,113 
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1.2.6 Current challenges in diagnosis and effectiveness of treatment 
Despite decades of research and significant understanding of endometriosis, the 
molecular mechanism and pathogenesis underlying its proliferation remains incompletely 
understood. The lack of a reliable non-invasive diagnostic test contributes considerably to an 
extended delay between the onset of symptoms and arriving at an accurate diagnosis of 
endometriosis (~7-12 years). The diagnostic challenge is further compounded by the unreliable 
correlation between clinical manifestations and surgical findings114 – as the ASRM clinical 
staging system assesses physical disease only and does not correlate with the severity of pain that 
patients experience. Often times patients with mild to minimal disease (stages I-II) experience 
excruciating pain, while those with severe disease (stages III-IV) may have no symptoms at all.  
However, establishing diagnoses on the basis of symptoms alone, can be complicated as 
women with endometriosis also have a high incidence of co-existing conditions, including 
allergies, asthma, fibromyalgia, irritable bowel syndrome, pelvic floor dysfunction, autoimmune 
disease, hypothyroidism, interstitial cystitis, chronic fatigue syndrome, and a low resistance to 
fevers.91 Moreover, as symptoms increase in severity, quality of life is further reduced owing to 
the significant negative impact on social, familial, sexual, educational, and professional aspects of 
daily life.88,115-117 
From a societal perspective, the economic burden from endometriosis is estimated at 
$119 billion/year (U.S.) for both direct and indirect costs, comparable to other chronic diseases 
though endometriosis is far less understood and often socially unaccepted.116,118 This substantial 
price tag assumes a 10 percent prevalence rate among women of reproductive age in the U.S., not 
reflecting the potential global financial burden with a total of 176 million women affected 
worldwide. Loss of productivity at work/school (~10-12 hours/week), involvement of multiple 
healthcare professionals, diagnostic and surgical procedures, “hit and miss” treatments, as well as 
costs of medicines, all factor in the direct and indirect costs of endometriosis to patients and 
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society. As a result, the average annual total societal cost per woman is estimated to be 
$16,116.118 In the U.S. alone, the associated costs of endometriosis has grown substantially from 
$15-22 billion in 2002, with a significant portion of that cost attributable to the expensive 
procedure of diagnostic laparoscopy.116,119-122  
Although hormonal suppression is an effective first-line approach for treating pain, it is 
not without risks or adverse side effects, as pharmacological agents are often of limited efficacy 
and counterproductive to fertility. Moreover, hormonal treatments have no long-term effect on 
endometriosis, therefore, surgical removal of endometriotic lesions is recommended and aims not 
only at reducing pain but is also considered the standard in treating endometriosis. Regardless of 
treatment, endometriotic lesions recur in more than 30% of patients, estimated at 40-50% within 5 
years, oftentimes with reduced fertility and increased pelvic pain.123,124 Despite the difficulties in 
distinguishing between recurrence and persistence of endometriosis,48 it is of utmost concern to 
monitor these patients over the years as their risk of cancer increases with  long-standing 
disease.125-129  
 
1.3 Linking PTEN to endometriosis and cancer 
1.3.1 Endometriosis and malignant transformation 
Endometriosis is considered to be a benign condition, however, it bears hallmarks of 
cancer such as development of local and distant foci and attachment to and invasion of other 
tissues with subsequent damage to targeted organs. The malignant transformation of 
endometriosis was reported as early as 1925,52,130,131 with a number of studies later identifying 
carcinomas arising from endometriosis of the colon,132,133 the bladder,134,135 the vagina,136,137 the 
vulva,138 and the abdominal wall.139-141 Research suggests that women with endometriosis may 
experience elevated risks of a variety of different types of cancer.126,127,129,142  
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Though early studies suggest a link between endometriosis and cancer,52,126,131,143,144 an 
exact frequency of malignant transformation is difficult to ascertain, however various values are 
reported in the literature.130 Studies have long suggested that ovarian and endometrial carcinoma 
arise through malignant transformation in 15-40% and 1% of all endometriosis cases, 
respectively.50,127,130,144-156 In fact, women with a prolonged history of ovarian endometriosis (>10 
years) and a diagnosis before age 30, had a higher relative risk for ovarian cancer.126  
 
1.3.2 Endometriosis and endometrial cancer risk 
 Although association between endometriosis and some subtypes of ovarian cancer has 
been well established, the association between endometriosis and endometrial cancer is not as 
thoroughly defined. However, an increased association between endometriosis and endometrial 
cancer has been established and is typically found in woman with advanced stage endometriosis 
(stage IV).157 Histological and immunohistochemical analyses classify endometrial cancer into 
two broad categories: type I (endometrioid (EMC) – variants: secretory EMC, endocervical 
adenocarcinoma, mixed-type adenocarcinoma) and type II (serous carcinoma, clear-cell 
carcinoma, and carcinosarcoma).158 The most common genetic alterations in type I include 
microsatellite instability and mutations in K-RAS, β-catenin, PTEN, and PIK3CA genes.159 In 
contrast, type II endometrial serous carcinoma, demonstrates mutations in TP53 gene and HER2 
overexpression or amplification.160,161 Type I accounts for ~80-85% of cases, whereas type II 
encompasses 10% of all endometrial cancer cases. 
Clinically, endometriosis has been identified in ~30% of cases with synchronous 
endometrioid type endometrial and ovarian cancers.155,162-164 In fact, 50% of women with ovarian 
endometrioid carcinomas also have simultaneous endometrial adenocarcinoma while 2-8% of 
patients with endometrial adenocarcinomas will have synchronous ovarian carcinoma; 
approximately 90% of synchronous tumors from ovary and endometrium will be endometrioid, 
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indicating they share common etiologic mechanisms.165 Mabrouk et al., reported a case of mixed 
clear-cell and endometrioid type adenocarcinoma of the extragonadal, rectovaginal septum 
arising from endometriosis and associated with differentiated, endometrioid endometrial 
carcinoma.166  
A premalignant lesion known as endometrial hyperplasia, is estimated to progress into 
invasive endometrial cancer in 5-10% of benign tumors and 20-30% of cases with accompanying 
atypia.167 Endometrial hyperplasia exhibits a frequency of 15% of K-RAS mutations similar to 
that seen in endometrial adenocarcinoma suggesting that this may be an early event in 
endometrial carcinogenesis.168 Maxwell et al., identified PTEN somatic mutations in 10/51 (20%) 
endometrial hyperplasia cases with no delineation in frequency between those with or without 
atypia, indicating that the mutation of PTEN is an early event in some endometrial cancers.169 
Moreover, patients with endometriosis exhibit endometrial hyperplasia and are at an increased 
risk of neoplastic transformation, though the exact risk of development into adenocarcinoma is 
currently unknown.170 The simultaneous detection of endometriosis, endometrial, and ovarian 
cancers, genetic mutation semblance in K-RAS and PTEN for endometrial cancer and endometrial 
hyperplasia, as well as the association of hyperplasia and atypia in endometriosis suggests that 
endometriosis may be a neoplastic process of endometrial cancer. 
 
1.3.3 Endometriosis and ovarian cancer risk 
Of all neoplasms, ovarian cancer has been the most consistently associated with 
endometriosis.171  This association was first identified in 192552,131 and has since been observed in 
a number of clinical cases among women with long-standing ovarian endometriosis126 and has 
been shown to occur at a high rate, in 4-29% of all cases.152,153 Epidemiologic, histopathologic, 
and molecular data suggest endometriosis may be a precursor lesion to specific types of ovarian 
cancer.149 Based on molecular genetic studies, epithelial ovarian cancer can be divided into two 
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categories:  type I  (endometrioid, clear-cell, mucinous, micropapillary serous carcinomas, and 
low-grade serous carcinomas) and type II (high grade serous carcinomas, carcinosarcoma, and 
undifferentiated carcinomas).  
Type I tumors develop slowly, and progress through a borderline precursor tumor stage 
such as endometriosis or low-malignant potential tumors. They are low-grade, confined to the 
ovary at diagnosis, genetically stable, and comprise ~25% of all ovarian cancers.130 They also 
demonstrate mutations in K-RAS, BRAF, CTNNB1, PTEN, TP53, BCL-2, and ARID1A 
genes.79,149,165,172 The greatest risk of endometriosis-associated malignancy are endometrioid and 
clear-cell carcinomas.173 Type II tumors are rapid growing, aggressive, malignant tumors without 
known precursor tumors. They are high-grade, with an origin of tubal epithelium, genetically 
unstable and demonstrate mutations in PIK3CA and TP53 genes,79,149,172 and HER2 expression.174 
Currently no association has been reported between endometriosis and mucinous or high-grade 
serous ovarian cancer.173   
Novel insights of the malignant transformation from endometriosis into ovarian 
carcinoma have identified pathologically, a morphological continuum of sequential steps from 
normal endometriotic epithelium to atypical endometriosis and finally to invasive ovarian 
carcinoma.175 In this study, researchers identified that atypical endometriosis and endometriosis-
related ovarian neoplasms share molecular alterations such as PTEN mutations, with ovarian 
endometrioid carcinoma harboring mutations in PTEN in 14-20% of the cases.175 This underpins 
a previous study where PTEN somatic mutations were identified in 4/20 ovarian endometrioid 
carcinomas (20%), 2/24 clear-cell (8.3%), and 7/34 solitary endometriotic cysts (20.6%).176 In 
fact, 5/7 of the endometrioid cases and 7/24 clear-cell cases had synchronous endometriosis. A 
separate study identified 22/37 of ovarian carcinomas with endometriosis demonstrated transition 
from typical endometriosis to atypical endometriosis, while 23/37 cases demonstrated atypical 
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endometriosis to carcinoma.177 This supports the emerging theory that endometriotic lesions 
potentially harbor genetic defects that are permissive to malignant transformation. 
 
1.3.4 PTEN somatic missense mutations associated with endometriosis, 
endometrial cancer, and ovarian cancer 
The tumor suppressor function of PTEN is dependent on its phospholipid phosphatase 
activity and the loss-of-function of the phosphatase catalytic domain is commonly associated with 
oncogenic PTEN mutations.4,178-180 Recently somatic mutations and deletions of PTEN have been 
reported in many types of sporadic tumors,181 including endometriosis,147 ovarian, and 
endometrial cancers.147,156,176,182-190 The incidence of PTEN mutations in endometrial tissue of 
women diagnosed with endometriosis and endometrial hyperplasia is one of the highest among 
analyzed tumors and the most commonly mutated gene identified in endometrial cancer.169,182 In 
fact, data suggests that PTEN is more commonly mutated than any other gene including K-ras 
and p53 in ovarian and endometrial cancers.169,182 The inactivation of PTEN has been described as 
an early event in endometrial hyperplasia and the development of ovarian and endometrial 
cancers.169,176,191 Thus, mutations and/or the loss of PTEN may contribute to the genesis and 
development of endometriosis and subsequently cancer. Therefore a thorough structural 
investigation of PTEN somatic mutations associated with endometriosis and endometrial and 
ovarian cancers will not only advance the understanding of genotype-phenotype interactions, but 
also further illuminate its molecular etiology. 
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1.4 Hypothesis and scope of research 
 Insights into the structural properties of PTEN provide a platform to analyze the 
mutations found in endometriosis, endometrial cancer, and ovarian cancer. Recent computational 
studies on PTEN reveal that missense mutations affect its function and structure.192,193 Therefore, 
a careful dissection into the effects of putative mutations is pertinent to understanding the 
molecular mechanism in each of the identified phenotypes proposed herein. 
In this study, thirteen somatic missense mutations were identified from published 
literature, offering a starting point to explore genotype-phenotype correlations in endometriosis, 
endometrial cancer, and ovarian cancer. We posit that the active-site of PTEN defines a possible 
mutation-driven allosteric region wherein a small subset of mutations correlate with 
endometriosis, endometrial cancer, and ovarian cancer. Our study focuses on understanding the 
impact that these missense mutations have on the structure of PTEN and on investigating the 
molecular mechanism of each of the phenotypes. It is our hope that the results from our study will 
aid in a better clinical-molecular classification of the resulting phenotypes and allow translation 
into improved diagnostic and therapeutic approaches. 
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Chapter 2: Theoretical background and methods 
2.1 pKa prediction 
The structure, stability, and function of proteins are dependent on their net charge and on 
the ionization state of individual residues.194 In essentially all biological reactions, there exists at 
least one step that involves the transfer of one proton group to another.195 The ease at which this 
transfer takes place (between an acid and a base) depends on the relative proton affinities of each 
group.195 Proton affinity is measured by the pKa value of an ionizable residue and is the 
logarithmic measure of the acid dissociation constant of a titratable group, which can be utilized 
as an indicator to determine the ionization of an amino acid at a given pH. The quantitative 
relationship between the pH of the solution and ion concentration is represented by the following 
ionization equilibrium reaction and Henderson-Hasselbach equation: 
 
 HA + H2O  →!!A- + H3O+ 
(Equation 2.1 Ionization equilibrium reaction) 
                                 Ka = 
A-  H3O+
HA
 
 
        pH =!pKa + log A-
HA
              (Equation 2.2 Henderson-Hasselbach equation)  
 
The pKa of a titratable site is therefore equal to the pH at which the site is 50% occupied 
by a proton. Table 2.1 references pKa’s of common ionizable residues alone in solution. The pKa 
values of ionizable residues however encounter several differences inside folded proteins 
compared to alone in solution. The factors that affect perturbation are a result of interactions of 
charged ionizable groups with neighboring residues (site-site interactions), electrostatic 
permanent dipoles in the protein (background interactions), as well as the altered interactions with 
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water (desolvation energy).194,196 However, perturbation is mostly due to electrostatic interactions 
of nearby residues.197  
 
Table 2.1 pKa of ionizable amino acids in solution 
Ionized state Neutral state pKa (solution) 
N-terminus, α-Amino (-NH3+) R - NH2 9.8 
C-terminus, α-Carboxyl (-COO-) R - COOH 2.2 
Guanidino, Arg (-NH2+) Arg (-NH) 12.4 
ε-Amino, Lys (-NH3+) Lys (-NH2) 10.4 
Phenol, Tyr (-O-) Tyr (-OH) 10.0 
Sulfhydryl, Cys (-S-) Cys (-SH) 8.3 
Imidazole, His (-NH+) His (-N) 6.3 
Non-α-Carboxyl, Glu (-COO-) Glu (-COOH) 4.4 
Non-α-Carboxyl, Asp (-COO-) Asp (-COOH) 4.0 
 
Knowing the pKa’s of residues and associated pKa shifts in their proteinaceous state 
allows for the determination and relative importance of the factors that affect perturbation in the 
aforementioned.  These pKa shifts reveal how much an ionizable residue retains or releases a 
proton and provides insight in to the local environment as to whether a residue is involved in 
catalysis, solvent exposed, or buried. Moreover, it is important to know that the charges and 
dipoles of the protein may stabilize or destabilize a charged state in the protein.198 Likewise, the 
desolvation impact when a charged group is brought from the highly polar aqueous solution into 
the typically apolar interior of the protein destabilizes charged effects.198 These are important 
factors to consider since when proteins are folded pKa perturbations on the surface of the protein 
are typically small and are determined by charge-charge interactions with other ionizable 
groups.199  
However, if these groups are partially or fully buried in the protein interior, large positive 
and negative perturbations often occur.200 Moreover, experimentally, mutations of charged 
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residues in proteins have been shown to be significant for the determination of molecular 
conformation.201 The suitable place to start when considering the calculation of pKa’s of each 
ionizable residue is to consider the difference between the pKa value of a model in its aqueous 
state as well as the pKa value of the ionizable residues in the protein. The pKa predictions 
evaluate the electrostatic potentials of ionizable residues by solving the Poisson-Boltzmann (PB) 
equation in order to produce protonation equilibria in proteins.197  
The University of Houston Brownian Dynamics (UHBD) program202 provides fast 
evaluation of various electrostatic energy terms for all ionizable residues of a protein utilizing the 
finite-difference Poisson-Boltzmann method (FDPB). This method is a numerical solution to the 
linearized Poisson-Boltzmann equation by which to calculate the self and interaction energies202-
204 of the ionizable groups in the protein:  
 ∇ ! ∙ !! ! ∇! ! = !−4!!! ! ! !+ !! ! !!! !           (Equation 2.3 Poisson-Boltzmann) 
 
where ε is the dielectric constant, ϕ is the electrostatic potential at position r to the density of the 
charge distribution ρf, λ delineates regions accessible to mobile ions and ! is a modified Debye-
Hückel parameter. The FDPB method allows the calculation of the free energy of a 
macromolecule in a given ionization state. These energies are required for the pairwise-
interaction energy grid utilized to calculate ionizable residue pKa shifts within a system. The free 
energy change of a given residue from the deprotonated state to the protonated state is obtained in 
the following equation: 
 ∆! = 2.303!!"# !" − !!!"!!                                   (Equation 2.4 Free energy change) 
 
where !"!!  is the intrinsic (experimental) pKa of the residue in solution and pH is that of the 
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environment. Thus the free energy of the ionization state (x1,…,xM) of the entire protein is: 
 
!!!!!!!!!!!!!!!!!!∆! !!,… , !! = !2.303!" !!!! !" − !!"!,!"#$%&'! ! 
(Equation 2.5 Free energy of ionization state) 
 
where xi is 1 when the group i is ionized and 0 when it is neutral. This equation allows for the 
analysis of electrostatic interaction of titratable residues within a protein, thus for a protein with 
M ionizable groups, the M ionization states and free energy state is expressed as: 
 
∆! !", !!! !,… , !!! = 2.303!" !!!!!!! !" − !!"!,!"#$%!"#!& + !!!!!!!"
!
!!!  
+ ! !!° + !!!! !!° + !!!! − !!!°!!°!!!!!! !!"
!
!!!  
(Equation 2.6 Additivity of electrostatic potentials) 
2.2 Generation of PTEN mutants 
 In silico modeling requires the three-dimensional structure of nucleic acids, proteins or 
biomolecular complex of interest. The Protein Data Bank (PDB)205 is a database that contains the 
structural data of biological molecules that were either determined via X-ray diffraction or 
through NMR experiments with approximations that comprise the atomic coordinates of the 
molecule of interest. Alternatively, if a structure has not been determined, a technique that 
enables the construction of a protein structure with known sequence can be carried out utilizing 
homology modeling which compares a protein with known sequence with an experimentally 
determined structure.206 If a mutant structure is required yet does not exist, one can be generated 
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in silico utilizing a variety of programs. One commonly used program is the Mutator module 
(v1.3) within the Visual Molecular Dynamics program (VMD).207 Mutant structures are built in 
silico by side-chain replacement starting from a predetermined wild-type (WT) protein structure.  
 
2.3 Electrostatic surface potential (ESP) calculation 
 Electrostatic interactions are a crucial property to understand as these interactions govern 
the folding of many proteins. A strong electrostatic field is produced by the many biological 
macromolecules that contain charged groups that are close to each other or at the surface and 
contribute to the overall charge density. Indeed, such interactions are used to stabilize a protein 
structure and are essential in governing protein-protein and protein-ligand interactions. These 
long-ranged interactions can accelerate the rate at which molecules associate.208 Electrostatic 
forces can steer the ligand into its binding site on the protein, which is critical to the function of 
the protein. In fact, weakly polar interactions depend on the electrostatic attraction between 
opposite charges. Some binding sites are naturally shielded from the solvent and are “closed” by 
salt links between groups on the protein surface. If the correct ‘charged’ substrate disrupts these 
salt links, it gains access to the binding site. Additionally, Electrostatic interactions between 
ligand and protein can contribute to the affinity and specificity of binding and orientation of the 
ligand. It is therefore essential to assess the surface charge distribution of a protein by calculating 
the electrostatic surface potential (ESP). 
Upon completion of the pKa calculation of each ionizable residue, an electrostatic surface 
potential map can be generated. In calculating electrostatics, one can solve the linear and non-
linear Poisson-Boltzmann (PB) equation using a finite difference method. The PB equation is a 
fundamental equation of classical electrostatics and is defined as: 
 ∇ ! ∙ !! ! ∇! ! = ! !                                                             (Equation 2.7 PB equation) 
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where ! is the electrostatic potential, ε is the dielectric constant (relative permittivity) of the 
medium (can be different throughout different regions of space), ρ is the charge density due to 
atomic charges and r is the position. !, ε, and ρ are all dependent on position. The Poisson 
equation indicates how the electrostatic potential due to distribution of charges in a heterogeneous 
dielectric environment varies throughout space.208 The Boltzmann equation indicates how the 
distribution of charged atoms of the salt varies with the electrostatic potential. Both of these 
equations must be solved simultaneously in order to determine the actual potential. 
 
Figure 2.1 Discretization schemes and hierarchies utilized in Poisson-Boltzmann solvers 
 
(A) Cartesian mesh suitable for finite difference (FD) calculation, (B) Finite element (FE) mesh 
exhibiting adaptive refinement, (C) Piecewise linear basis function used in FE methods, (D) 
Multi-level hierarchy used to solve the PB equations for an FD, (E) Multi-level hierarchy used to 
solve the PB equation for FE discretizations; red lines denote the simplex subdivisions used to 
introduce additional unknowns at each hierarchy level. 
From Baker, N.A.209 
 Methods for solving the PB equation have been developed to improve the efficiency of 
electrostatic calculations the most common methods include: finite difference (FD), finite element 
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(FE), and boundary element methods (BEM) (see Figure 2.1) - the former being the most popular 
method.209 In the finite difference (FD) method, the space is discretized (chopped up in discrete 
chunks).208 The FD method solves the PB equation on a non-uniform Cartesian mesh for a two-
dimensional domain. The Poisson differential operator is transformed in a sparse difference 
matrix by means of a Taylor Series expansion. The resulting matrix equations are then solved by 
various linear algebra techniques. In the adaptive finite element (FE) method finite element 
meshes are composed of triangles or tetrahedra that are joined at edges and vertices. Solution 
accuracy can be increased in specific areas by locally increasing the number of vertices through 
simplex refinement.209 The ability to locally increase the solution resolution is called “adaptivity” 
and is the major strength of FE methods applied to the equation. 
 
2.4 Multiple sequence alignment (MSA) – sequence 
conservation 
 Multiple sequence alignment (MSA) involves the alignment of three or more biological 
sequences of similar length. From the output, homology can be inferred and the evolutionary 
relationships between the sequences are assessed. There are multiple methodologies to compute 
MSAs some of which require more sophisticated methodologies than pairwise alignment. 
However, most MSA programs utilize heuristic (progressive) methods, as it can be a prohibitive 
computational expense in calculating an optimal alignment. The most widely utilized progressive 
alignment algorithm is CLUSTAL W.210 Three steps utilized in all progressive alignment 
algorithms are: (i) calculation of pairwise distances based on pairwise alignment of the sequences  
(percent identity), (ii) build a guide tree which is an inferred phylogeny for the sequences, and 
(iii) utilize the tree to guide the progressive alignment. There are many ways to build a tree from 
a matrix of pairwise distances. CLUSTAL W uses the neighbor-joining method.210 A root of the 
!!30 
tree is then determined by the mid-point method, which gives equal means for the branch lengths 
on either side of the root. The Weights (CLUSTAL W) are then calculated correcting for unequal 
sampling at different evolutionary distances.210 A multiple alignment editor such as Jalview211 can 
be utilized to align and visualize the sequences. 
 
2.5 Elastic network model – normal mode analysis (NMA) 
 Normal mode analysis (NMA) is a simulation technique utilized to probe, large scale 
motions in macromolecular molecules. Traditionally used in infrared and Raman spectroscopy 
experimental techniques, NMA has demonstrated in more recent developments, that it is capable 
of providing unique insights into the structural and dynamic properties of complex systems as 
well as in the prediction of functional motions in biomolecules. Formally NMA involves a 
Hessian matrix inversion process that limits its applicability to large systems; however both 
numerical and approximate methods have been developed to extend the size limit. This can be 
computational demanding as it involves the diagonalization of a 3N x 3N matrix, where N is the 
number of atoms in the molecule.  
One of the more recent developments is the use of simplified coarse-grained (CG) NMA, 
known as elastic network model (ENM) NMA as an alternative to full atomic, “standard” NMA. 
This method has two advantages over the standard NMA: (i) energy minimization is not 
necessary because all of the distances of all of the elastic connections are taken to be at their 
minimum-energy length (ii) diagonalization is substantially reduced because the number of atoms 
is reduced as only Cα atoms are utilized. This results in a ten-fold reduction in the number of 
atoms, thus greatly reduces the computational time. In contrast to standard NMA, ENMs require 
two assigned parameters: (i) the force or spring constant denoted as γ, and (ii) a cut-off distance 
denoted as, Rc.212 As evidenced by a pioneering study of Tirion,213 a hypothetical force field with 
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uniform (single-parameter) harmonic potentials yields global modes almost indistinguishable 
from those obtained from a detailed force field with specific nonlinear terms.214 The shape of the 
global modes is dominated by the network of inter-residue contacts, which is a purely geometric 
quantity defined by the overall shape, form, or native contact topology of the protein.214  
Inspired by the work of Tirion,213 the Gaussian network model (GNM)215,216 was the 
first simplified ENM and is based on the theory of elasticity.217-221 The GNM involves a single 
site per residue representation, in which the sites are identified by the Cα atoms and described as 
an elastic network connected by a uniform spring force constant, γ, provided that they are within 
a certain cut-off distance, Rc (Figure 2.2). The dynamics of the interconnected bead-and-spring 
model best described by the GNM, uses the following potential: 
 !!"# = ! !! !!" − !!!"! !! !! − !!!"!!,!                             (Equation 2.8 GNM potential) 
 
where γ is the uniform spring constant, !!"!  and !!" are the original and instantaneous distance 
vectors between i and j; the summation is performed over the pairs of residues/nodes filtered 
through the heavy step function ! !! − !!!"  and selects the interacting pairs within the cut-off of 
rc and is also equal to 1 if the argument is positive, and zero otherwise. 
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Figure 2.2 Harmonic spring network interaction sites and displacements 
 
From https://en.wikipedia.org/wiki/Gaussian_network_model 
 
The GNM is based on the assumption that all residue fluctuations (and inter-residue 
distances) are Gaussianly distributed around their equilibrium coordinates. The equilibrium 
coordinates are identified by the position vectors !!"!  of Cα atoms in a protein structure. The 
Hessian matrix (standard NMA) is replaced by an N x N Kirchoff matrix, which describes the 
inter-residue contact topology, Γ, such that N-1 isotropic modes are obtained, and is the sole 
determinant of equilibrium dynamics. The fluctuations and their cross-correlations are fully 
controlled by the matric. The Kirchoff matrix, Γ is defined by: 
 
Γ!" = ! −10− Γ!"!!,!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"!!! ≠ !!!"#!!!"! < !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"!!! ≠ !!!"#!!!" > ! !!!"!! = !  
(Equation 2.9 Kirchoff matrix) 
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where rc is a cutoff distance for spatial interactions, usually 7 Å for proteins.222 
Another broadly utilized ENM is the anisotropic network model (ANM).223-226  Similar 
to the GNM, the positions of the nodes in the ANM are identified but the Cα atoms, however, the 
ANM potential is defined as: !!"# = ! !! !!" − !!!"! !! !! − !!!"!!,!                             (Equation 2.10 ANM potential) 
 
with the central difference between GNM and the above potential being that the vectors !!"!   and !!" in equation 2.10 replaces distances (scalars), !!"! ! and !!". This indicates that the potential 
depends on their scalar product rather than upon the dot product between the fluctuation vectors 
as in the GNM. Here V = 0, if !!" = !!"!  irrespective of the direction of the corresponding distance 
vectors. An rc = 12-15 Å provides a good description of the native contact topology. The ANM 
requires the eigenvalue decomposition of the Hessian H (second derivative of potential, V), a 3N 
x 3N matrix composed of N x N elements, !!" ! ! ≠ !!  defined as: 
 
!!" = ! !!!"!!"! ! !!!"!!" !!"!!" !!"!!"!!"!!" !!"!!" !!"!!"!!"!!" !!"!!" !!"!!"                                 (Equation 2.11 Hessian matrix) 
 
where !!" ,!!" , and!!!" are the components of the distance vector,!!!"!  . The pseudo-inverse of H is 
the 3N x 3N covariance matrix, CANM, which can be expressed in terms of the 3N-6 non-zero 
eigenvalues λk and corresponding eigenvectors uk of H and described as: 
 !!"# = ! !!! !!!!!!!!!!!!                                      (Equation 2.12 ANM covariance matrix) 
 
The ANM has been shown alongside standard NMA to match closely the collective 
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motions along the second lowest frequency mode intrinsically accessible to the original structure 
of hemoglobin demonstrating the allosteric change in conformation from its tense form (T) to its 
relaxed (R) form.227,228 The main advantages of ENM-based approaches such as the GNM and the 
ANM are for their (i) ability to provide an exact solution for the unique dynamics of a structure 
and (ii) applicability to large biomolecular complexes and assemblies beyond the range of atomic 
simulations.214  It is suggested that the GNM be utilized (rather than ANM) for evaluating mean-
square fluctuations of residues and their cross-correlations, as well as the profiles of residue 
displacement sizes in collective modes, and that the ANM be utilized for exploring properties that 
cannot be calculated using the GNM such as deformation vectors or molecular motions.229 
 
2.6 Elastic network model – protein structure network (PSN)  
 Protein structure network (PSN) analysis is an extension of the ENM-NMA outlined in 
the previous section see (section 2.5). The concept of PSN has been explored more recently as it 
offers insights into the global properties of protein structures.230,231 The representation of protein 
structures as networks of interactions between amino acids has proven useful in a number of 
studies, such as protein folding232 and prediction of functionally important residues in enzyme 
families;233 therefore contributing to the issue of intra-molecular and inter-molecular 
communication.230,231 Based on early work established by Vishveshwara et al.,234,235 PSN is 
constructed from the atomic coordinates of residues, which represent the nodes of the network. 
Two nodes are connected by an edge if the percentage of the interaction between them is greater 
than or equal to a given Interaction Strength cut-off.  
 !!" = ! !!"!!"!!" 100                                   (Equation 2.13 PSN-Interaction Strength cut-off) 
where Iij is the interaction percentage of nodes i and j, is the number of side-chain atom pairs 
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within a given cut-off (4.5 Å), and Ni and Nj are, respectively, the normalization factors (NF) for 
residues i and j, which take into account the difference in size of different nodes and their 
propensity to make the maximum number of contacts with other nodes within protein structures. 
  This PSN method lends itself to a recently implemented mixed PSN-ENM approach to 
predict salient structural communication pathway in biomolecular systems. The underpinning of 
WebPSN236 lies with a Protein Structure Graph (PSG) and searches for all shortest 
communication pathways between user-specified residues. A PSG defines amino acids as nodes 
and the noncovalent interactions among them as links. Such graphs are useful in identifying 
clusters of residues that stabilize the protein structure and protein-protein interfaces.234 The 
network topology of PSGs depends on the cut-off of the interaction strength between residues 
used in the constructed graph.      
The mixed PSN-ENM method (WebPSN) involves a multi-step process (Figure 2.3) 
where network features (i.e. nodes, hubs, links) are computed by building a PSG and the shortest 
communication pathways on ensembles of structures are acquired from a single high-resolution 
structure. The algorithm defines all possible communication paths between selected node pairs 
and filters the results to cross-correlation of atomic motions, as derived from ENM-NM. Filtering 
consists in retaining only the shortest path(s) that contains at least one residue correlated (i.e. with 
a cross-correlation value ≥0.6) with either one of the two extremes (i.e. the first and last residues 
in the path). Meta-paths made of the most recurrent nodes and links in the path pool (i.e. global 
meta-paths) and infer a coarse/global picture of the structural communication in the considered 
system. In detail, meta-paths are made of nodes ≥5% of the considered path pool (i.e. ‘frequent 
nodes’), and of links satisfying both conditions of being present in of the paths and of connecting 
‘frequent nodes’.  
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Figure 2.3 Mixed PSN-ENM WebPSN flowchart 
 
 
Adapted from Seeber, M. et al.236 
 
 A recent study demonstrated the advantages of utilizing this mixed PSN-ENM approach 
on a domain in its free state and in complex with a C-terminal peptide illustrating salient 
communication features within each system.237 The benefits of this high-speed approach are well-
suited for high-throughput investigation of the structural communication pathways including 
allosterism, in large biomolecular systems in different functional states.236  
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2.7 Structural stability prediction 
 Many computational methods have been developed to predict the overall structural 
stability of a protein as the result of the introduction of a mutation. The core functionality of these 
methods involves an energy function that calculates the free energy of the system. Many of these 
functions were also developed to estimate the consequence of a mutation on protein stability or 
binding affinity.238 Though three-dimensional structures provide atomic details on their 
architecture, but not on the forces stabilizing them.238 Introducing mutations and quantifying their 
energetic consequence can assist in assessing these forces. Most of the mutations either are 
neutral or destabilize protein structure; however many stabilizing mutants have demonstrated to 
be advantageous to protein function.239 
Three common programs utilized to predict protein structure stability are: I-Mutant 3.0,240 
CUPSAT,241 and Elastic Network Contact Model (ENCoM).242,243 I-Mutant 3.0 is a support 
vector machine (SVM)-based tool that calculates protein stability changes upon mutation either 
from sequence or structural information.240 The structure-based version of I-Mutant 3.0, classifies 
the prediction into one of three classes: neutral mutation (-0.5 ≤ ∆∆G ≥ 0.5 kcal/mol), large 
decrease (<-0.5 kcal/mol), or large increase (>0.5 kcal/mol).240 The predicted free energy change 
∆∆G is based on the difference between unfolding Gibbs free energy change of mutant and native 
protein (kcal/mol).240 CUPSAT is a physiochemical modeling program that utilizes a Boltzmann 
mean-force potential and torsion angles (phi, psi) to predict ∆∆G values and stability changes.241 
CUPSAT also calculates the overall stability change as well as the adaptation (favorable or 
unfavorable) of the observed torsion angles (phi, psi) as a result of the mutation. ENCoM242,243 
utilizes a novel mixed coarse-grained normal mode method to account for the type and extent of 
pairwise atomic interactions allowing for the calculation of vibrational entropy differences as a 
result of mutations.242,243 ENCoM utilizes a potential function with four terms: (1) covalent bond 
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stretching, (2) angle bending, (3) dihedral torsion, and (4) non-bonded interaction while taking 
into consideration the nature and possible effects that the orientation of the side-chains have on 
dynamics within the context of normal mode analysis. Utilizing computational methods to predict 
structure stability changes upon mutation can assist in designing new or mutated protein with 
specific levels of stability, enzymatic activity and binding to other molecules (proteins, DNA, 
ligands, substrates, etc.) further stabilizing its function.238 
 
2.8 Molecular dynamics (MD) simulations 
In modern molecular modeling, molecular dynamics (MD) simulation is a very powerful 
technique that aims to understand the properties of assemblies of molecules in terms of structure 
and microscopic interactions between them by simulating their behavior in silico.244 Molecular 
dynamics enables the study of complex dynamic processes that occur in biological systems and is 
a useful technique for the characterization of macromolecular stability, protein folding, dynamics 
and flexibility, conformational and allosteric properties, molecular recognition (properties of 
complexes), and ion transport on the nanosecond, microsecond and millisecond time scale.245,246 
Extraction of these macroscopic observables, therefore, allows for the prediction of mechanisms 
and a greater understanding of conformational changes in a protein.247 Molecular dynamics offers 
the opportunity to perform a wide variety of studies, which include both drug and protein design. 
Molecular dynamics simulations are in many respects very similar to conventional (wet-
lab) experiments. When a conventional experiment is performed, the following occurs: 
preparation of sample, connect sample to instrument (i.e. thermometer, fluorescence microscope), 
and measure the property of interest over a certain interval.248 In a molecular dynamics 
simulation, the same approach is followed: first a sample is prepared by selecting a model system 
of N particles and then Newtown’s equations of motion are solved until the properties of the 
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system no longer change over time (equilibration). After equilibration, the actual measurement is 
performed as a function of the positions and momenta of the particles in the system.248 These 
simulations are referred to as entirely classical since only classical Newtonian dynamics 
(equations of motion) are utilized – quantum and reactive processes are not calculated.  
As conventional experimental approaches reach a maximal resolution of ms-µs in time, 
and a length order of nm, theoretical (simulation) models allow simulating the microscopic level 
at atomic resolution, but only on the order of 102 ns/101 nm for small systems. For most 
biomolecular systems, however, it is often necessary to work with empirical parameterizations of 
models, which are orders of magnitude faster and have the ability to produce observations on a 
much greater timescale (Table 2.2). 
Table 2.2 Timescales and amplitudes of biomolecular motions 
 
Timescale Amplitude Description 
  Local Motions 
Short: femto, pico 
10-15 – 10-12 s 
0.001 – 0.1 Å 
-Atomic fluctuations: bond stretching, 
angle bending, dihedral motion 
-Side-chain motions 
-Loop motions 
  Rigid Body Motions 
Medium: pico, nano 
10-12 – 10-9 s 
0.1 – 10 Å 
 
-Helix motions 
-Water relaxation 
-Collective motions: subunit ad domain 
motions (hinge bending, twisting) 
  Large-Scale Motions 
Long: nano, micro 
10-9 – 10-6 s 
1 – 100 Å 
 
-Folding in small peptides 
-Helix coil transitions 
-Dissociation/association 
-Ion transport 
  Very Large-Scale Motions 
Very long: micro, second 
10-6 – 10-1 s 
10 – 100 Å 
 
-Folding and unfolding 
-Ribosome synthesis 
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Essentially, molecular dynamics generates configurations of a N-body system by 
integration of Newton’s laws of motion and calculates the time-dependence of that molecular 
system.249,250 To begin, a MD simulation algorithm needs only an initial configuration of the 
system, r (atomic coordinates), and a force-field, E(r). Given the potential and force (negative 
gradient potential) acceleration can be calculated: 
 !! = ! !"!!!! = !!!!!                                                                             (Equation 2.14 Force) 
From the integration of the acceleration, velocities are calculated: !!! = ! !!!!"                                                                             (Equation 2.15 Velocities) 
With the integration of velocities, a new set of positions are calculated: !!! = ! !! !!"                                                                              (Equation 2.16 Positions) 
 
The equations of motion are integrated numerically and broken into many small fixed 
time steps, δt.250 The total force on each atom in the configuration is calculated from the vector 
sum of interactions with other atoms at time t. Using the Newtonian equation, an algorithm 
iteratively calculates forces by solving equations of motion and assigning positions based on 
accelerations, with increasing time. The resulting trajectories are defined by both position and 
velocity vectors and describe the time evolution of the system representing the conformational 
phase space of the system.  
 
 2.8.1 The Verlet and leap-frog algorithms 
Numerous algorithms exist for integrating the equations of motion and can be a rather 
simple calculation for a two-atom system. However, the number of atoms increases for a system 
with many particles, for which the finite difference approach is used to integrate the equations of 
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motion. The algorithm must be able to conserve energy and momentum, be time-reversible, and 
permit a long time step, δt. Given the molecular positions, velocities, and other dynamic 
information at time t, the positions and velocities can be obtained based on acceleration over time 
(t + δt).251 This loop of calculations is integrated iteratively at new positions, for a fixed time step 
in order to obtain new values at time t + 2δt.250 All algorithms assume that the positions and 
dynamic properties (velocities, accelerations, etc.) can be approximated as Taylor series 
expansions: 
r(t + δt) = r(t) + δtv(t) + !!δt2a(t) + 1/6 δt3b(t) + …        
v(t + δt) = v(t) +δta(t) + !!δt2b(t) + …                                                        
a(t + δt) = a(t) + δtb(t) + …                              (Equation 2.17 Taylor Series Expansions)                                                                                                                                            
b(t + δt) = b(t) + …   
From Leach, A.R., 2001250 and Allen, M.P. and Tildesley, D.J.251 
where r and v represent the complete set of positions and velocities (the first derivative of the 
positions with respect to time), a represents all accelerations (the second derivative), b denotes all 
third derivatives of r. 
The initial step in solving the equation of motion is to discretize the time by solving r(t) 
on a series of time instances ti. The most employed algorithm in discrete time is the Verlet252 
algorithm, which utilizes positions and accelerations at time, t, as well as positions at the previous 
step r(t + δt), to calculate the new positions at t + δt, r(t + δt)250 is given by:  
 ! !! + !!" != 2! ! − ! !! + !!" !+ !!!!! !                                (Equation 2.18 Verlet) 
 
A variation on the Verlet algorithm is the leap-frog253 algorithm which calculates 
positions at time t, velocities at time ! − !!! !"!  and is given by: 
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! !! + !!" != ! ! !+ !!"# !! + !!! !"                                       (Equation 2.19 Leap-frog) 
 ! ! + !!! !" = ! !! − !!! !" !+ !!"# ! !
From Allen, M.P. and Tildesley, D.J.251 
Here the velocities are always calculated at intermediate steps between two subsequent 
position calculations. The stored quantities are the current positions r(t) and accelerations a(t) 
together with mid-step velocities!! ! + !!! !" . The velocity equation is implemented first and the 
velocities leap over the coordinates to give the mid-step values. This is necessary so that the 
energy at time t can be calculated as well as any other quantities that require positions and 
velocities at the same instant.251  
 
2.8.2 Potential energy function 
 In addition to the coordinates and velocities, the forces of the system are calculated by an 
empirical potential energy function, or force field. The effective molecular energy can be 
described as a sum of potentials derived from simple physical forces, which include both bonded 
(covalently linked atoms) energy terms, non-bonded (non-covalent) interaction terms and 
optional terms (constraints): 
 !!"#$% != !!!"#$%$ !+ !!!"!#"!$%$ !+ !!!"#$!%&'!!"#$%                             
(Equation 2.20 Potential energy, Force field) 
 
For bonded (intramolecular) interactions the potential is usually a sum of harmonic and 
Fourier terms in order to model energy of stretching, bending, and torsion motions between 
covalently bound atoms described as: 
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!!"#$%$ != !!"#$%! + !!!"#$%& !+ !!!"!!"#$%&  
 
Figure 2.4 Potential energy function (bonded terms)  
 
 
= !Σ!"#$% !!2 ! !!! − ! !!,! ! !+ !Σ!"#$%& !!!2 ! !! !− !!!,! !! + Σ !"#$%#&$!"!!"#$%&!! !!2 ! !! !− !!!,! !
+ !!Σ !"#!$"!"!!"#$% !!!2 ! 1 + !cos !"! − !! ! 
(Equation 2.21 Bonded terms) 
 
where l represents bond length, θ  the deviation from the ideal bond angle, !!!   is the associated 
force constant, and !!! , ω, and γ are the amplitudes, dihedral angle and phase angle associated 
with Fourier terms. Two forms are used for the four-body dihedral angle interactions: a harmonic 
term for improper dihedral angles ζ, that are not allowed to make transitions (i.e. dihedral angles 
in aromatic rings) and a sinusoidal term for the proper dihedral angles ω, which make 360 degree 
turns.254 The non-bonded (intermolecular) interactions are modeled with a sum of over all pairs of 
atoms composed of van der Waals (Lennard-Jones) potential to account for dispersion and 
repulsion terms and Coulomb  (electrostatic) potential to account for partially charged atoms: 
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!!"!#"!$%$ = !!!"#!!"#! ""#$ !+ !!!"!#$%&'$($)# ! 
= Σ!!!! !Σ!!!!!! ! 4!!" ! !!"!!" !" !– ! !!"!!" ! !+ ! !!!!4!!!!!"  
(Equation 2.22 Non-bonded terms) 
where the van der Waals term expresses the interaction energy between two atoms (containing 
both repulsive r12 and attractive r6 parts), rij represents the distance between atoms i and j with 
charges !!!and !!, ε represents the dielectric constant. The calculation of Coulomb interactions 
are the most time consuming as it is evaluated by means of a pairwise additive potential; therefore 
the number of contributions for N-particles of a system is N(N-1)/2 and scales as N2.254 As this 
represents the highest percentage of computational resources employed in MD simulations, many 
efficient algorithms have been developed to save computational time in the evaluation of this 
term. 
 
2.8.3 Computational efficiency methods  
2.8.3.1 PME method 
 Due to the prohibitive computational cost and difficulty it takes to calculate long-range 
electrostatic pairwise interactions several techniques have been developed.  The most popular and 
efficient technique is known as the Particle-Mesh-Ewald (PME) method255 which calculates 
long-range forces within a finite distance using a modification of Coulomb’s Law and in 
reciprocal space using a Fourier transform to build a “mesh” of charges, interpolated onto a 
grid.255 The fast Fourier algorithm scales as N lnN, which gives considerable advantages over the 
N2 alternative.250  
The Fourier coefficient of the mesh-based charge density is computed and then the 
potential on each particle is transformed back incorporating them into the non-bonded 
interactions. This method is capable of achieving high accuracy and is markedly efficient as it 
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evaluates the long-range forces by analytically differentiating the energies, thus reducing memory 
requirements substantially with relatively little increase in computational cost.256 
 
2.8.3.2 United atom force field 
 As the number of non-bonded interactions scales with the squared number of interaction 
sites, the computational expense also greatly increases.250 It is therefore advantageous to reduce 
the number of interaction sites in order to save computational time by employing a united atom 
model where several atoms are joined into a single interaction site. In this approach, non-polar 
hydrogens atoms in methyl (CH3) and methylene (CH2) groups do not have explicit representation 
and instead are represented by a single united atom.  
 
Figure 2.5 United atom representation 
 
 
Adapted from Leach, A. R., 2001250 
 
In this way, not only are the explicitly simulated degrees of freedom reduced, but also the 
number of atoms in the system. This yields a reduction of computational effort up to a factor of 
nine at the expense of neglecting the slight directional and volume effects of the presence of the 
hydrogens.257 The forces between the interaction sites act on the united atom mass center, which 
remains located on the carbon atom (with a mass of 15 for a CH3 group and 14 for a CH2 
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group).250 Polar hydrogens are represented explicitly so that they are available to participate in 
hydrogen-bonding interactions.  
 
2.8.3.3 Constraints and restraints 
 Another way to increase simulation efficiency is to apply constraints or restraints to bond 
lengths or angles. Since MD simulations involve three time scales: the integration time step (δt), 
the total simulation time t, and the time scale of the process of interest τr, the time step needs t to 
be small enough so the changes in the forces over one step are small in order to describe the 
correct motion of the particles in a system.258  Moreover, the length of the time step in a MD 
simulation is limited by high frequency internal motions occurring in the system (Figure 2.6).254 
In freezing the high vibration frequencies by constraining the bonds lengths or angles, vibrations 
are removed; therefore increasing the time step and computational efficiency is increased by a 
factor of 3.  
 
Figure 2.6 Vibrational frequency timescale 
 
 
Constraints or restraints have been developed for the constraining of the fastest degrees 
of freedom. In constraint dynamics, bonds or angles are forced to adopt specific values (fixed) 
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throughout a simulation without affecting the other internal degrees of freedom, whereas in 
applying restraints, the bonds or angles have the ability to deviate from the desired value.250 
When constraints are applied to all bond lengths or those involving only hydrogen atoms, stable 
trajectories with δt = 2 fs can be obtained.258 When restraints are placed upon a bond or angle, it 
is able to deviate from the desired value; the restraint only acts to ‘encourage’ a particular 
value.250 Typically both distance (length) and dihedral (angle) constraints are optional terms of 
the potential energy function (see Equation 2.22) and are introduced using harmonic interactions: 
 !!"! = !Σ! !! !! !− !!!" !                                             (Equation 2.23 Constraint distance) 
 !!" = !Σ! ! ! !! !− !!!" !                                          (Equation 2.24 Constraint dihedral) 
From Becker, O.M. and Karplus, M.259 
 
where Ki are the ‘force’ constants and rio, ϕio are the target distance and dihedral values, 
respectively. 
There are several methods available to apply constraints; the more common are the 
SHAKE260 and LINear Constraint Solver (LINCS)261 algorithms. In the SHAKE260 algorithm, 
(iterative, slow) bond lengths or angles are constrained at their ideal values so that their stretching 
motions are not integrated prior to applying the rigid constraints.259 The LINCS algorithm (non-
iterative, fast) directly resets the constraints rather than the derivatives of the constraints.262! A 
critical aspect to consider is that constraints are assessed as additional energy terms, acting as 
‘penalty functions’; if they are not satisfied, the energy increases significantly.259 Therefore it is 
necessary to turn off the constraints as the energy of the conformation is calculated. 
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2.8.4 Water models 
 Molecular dynamics simulations involve a large number of water molecules and despite 
their small size, the calculation of non-bonded interactions between pairs of molecules and water 
accounts for most of the computational time. Most force fields utilize effective pairwise potentials 
to simulate liquid water, which then determines the computational efficiency.250 Several water 
models have been developed and consist of three types: simple, flexible, and polarizable. Simple 
models represent a fixed (rigid) atom position where the interaction between the molecules is 
described using Coulombic and Lennard-Jones expressions. Flexible models represent atoms on a 
“spring” and enable internal changes in conformation. Polarizable models account for explicit 
polarization and many-body effects.  
Simple water models are the most commonly used and consist between three to five 
interaction sites, which differentiate in the way that partial charges are distributed within the 
molecule.263 Regardless of the number of sites, it is important that a single Lennard-Jones 
interaction site is located on the oxygen atom.263 Common models with three interaction sites for 
the electrostatic interactions are SPC264 and TIP3P265 where the hydrogen atoms have partial 
positive charges that are balanced by a negative charge on the oxygen atom. The Lennard-Jones 
potential accounts for the van der Waals interaction between two water molecules based on the 
oxygen atom only and the Coulombic term accounts for the electrostatic interaction. The potential 
is given by the following equation:  
 
= Σ!!!! !Σ!!!!!! ! 4!!" ! !!"!!" !" !– ! !!"!!" ! !+ ! !!!!!!!!!!"         (Equation 2.25 Potential) 
where  σ ij is the collision diameter, ε ij is the well-depth, ε0 is the dielectric constant, and rij is the 
distance between two charged atoms i and j with partial charges qi and qj. The effective dipole 
moment of the SPC264 model is 2.27 D and 2.34 D for TIP3P265, which are close to the dipole 
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moment of liquid water (~2.6 D). Both models demonstrate good agreement between experiment 
and theoretical calculations of water with SPC264 offering faster diffusion and TIP3P265 faster 
dynamics.263 The geometry and designated charges of the SPC264 and TIP3P265 water models are 
as follows: 
 
Figure 2.7 SPC and TIP3P 3-site water model 
 
 
Adapted from Leach, A. R., 2001250 
 
 
2.8.5 Setting up MD simulations 
Molecular dynamics simulations involve numerically integrating equations of motion for 
a many-body system. When using Cartesian coordinates, one can integrate Newton’s second law 
of motion to obtain the dynamical trajectory for each particle. Therefore, to begin a MD 
simulation an initial configuration (positions and velocities) of the system of interest must be 
chosen based on experimental or theoretical data such as a homology model, NMR structure, or 
X-ray crystal structure obtained from the Protein Data Bank (PDB).205 The initial configuration 
must be chosen carefully as this can influence the quality of the simulation. The simulation itself 
can be broken down into several steps: 
 
 
!!50 
Figure 2.8 MD simulation steps 
 
 
Choosing an appropriate time step, δt, must also be carefully considered; not too short so 
that conformations are sampled and not too long to prevent uncontrolled fluctuations. An order of 
magnitude less than the fastest motion is typically ideal - typically bond stretching is fastest 
motion, ~10 fs; therefore 1-2 fs is recommended.  The initialization phase proceeds when initial 
velocities, vi, are randomly assigned to atoms to generate a Maxwell-Boltzmann distribution 
which gives the probability, p(vix), that an atom i has a velocity, vx, in the x direction at a given 
temperature: 
! !!" != ! !!!!!!! !/! !"# − !!!!!!"!!!!        (Equation 2.26 Maxwell-Boltzmann distribution) 
From Leach, A. R., 2001250 
Once the initial velocities are assigned, energy minimization is subsequently performed 
which allows water molecules to adjust to the protein and removes any existing strong van der 
Waals interactions which might otherwise lead to local structural distortion and result in an 
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unstable simulation. Following energy minimization, the system is then equilibrated where the 
temperature is systematically increased from 0 K to a desired temperature (i.e. depends on 
system: 273 K for room temperature or between 300-310 K if body temperature is desired). 
During this phase, the initial velocities are assigned at a low temperature and gradually scaled 
upward by means of a thermostat; therefore allowing the process to continue until the desired 
temperature and a Maxwell-Boltzmann distribution is achieved. Additionally, the integration step 
is appointed where the force on each atom is calculated by differentiating the potential function. 
Thermodynamic and structural properties are monitored throughout equilibration until stability is 
achieved. 
Once equilibration has been attained at the desired temperature and pressure, the final 
production phase is initiated and carried out in a desired thermodynamic ensemble (i.e. isobaric-
isothermal, NPT ensemble, where the number of atoms of atoms, N, pressure, P and temperature, 
T are fixed). During this phase thermodynamic properties are derived from Newton’s to obtain 
atomic positions and velocities as a function of time. 
 
2.8.6 Periodic boundary conditions 
 Boundary effects play a critical role in MD simulations since the size of a system is 
finite; therefore the correct treatment of boundaries are necessary to minimize edge effects and 
avoid surface artifacts. Periodic boundary conditions (PBC) enable a simulation to be performed 
using a relative small number of particles in such a way that the particles experience forces as if 
they were in bulk fluid.250 When applying PBC the atoms of the system are placed in a pre-
defined box (cubic or rectangular), or more generally into a periodic space-filling box, which is 
surrounded by identical, translated copies of itself. When an atom exits the central box at one 
side, it enters it with identical velocity at the opposite side at the translate image position. This 
process is intimately related to non-bonded interactions, where the forces are summed over all 
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neighbors in the infinite periodic system and only coordinates from the central box are stored 
throughout the simulation.  
 
Figure 2.9 Periodic boundary conditions 
 
 
2.8.7 NPT ensemble 
When performing MD simulations, it is critical to keep the certain state variables (i.e. 
temperature and pressure) of the system constant throughout the duration of the simulation in 
order to mimic previous experimental (macroscopic) conditions. Depending on which state 
variables are kept fixed (i.e. energy E, volume V, temperature T, Pressure P, and number of 
particles N), different statistical ensembles can be generated (Table 2.3). A variety of properties 
(structural, energetic, and dynamic) can then be calculated from the averages or fluctuations of 
these quantities over the ensembles.  
The constant-pressure, constant-temperature (NPT) ensemble can be employed 
throughout the production phase of a MD simulation, as it compares with experimental results 
where conformational changes, protein-ligand and drug-target binding have been modeled under 
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constant temperature and pressure. The NPT ensemble is maintained by coupling the system to an 
external ‘heat bath’ (thermostat), at a fixed temperature.266 Similarly to maintain pressure, the 
system is coupled to an external ‘pressure bath’ (barostat). The baths supply or remove heat or 
pressure from the system as needed and scales the velocities at each time step.  
Table 2.3 Thermodynamic ensembles  
Thermodynamic Ensembles 
Select one from each row 
Particle number, N Chemical potential, µ 
Volume, V Pressure, P 
Energy, E Temperature, T 
 
 
2.8.8 Analysis 
Molecular dynamics simulations can be analyzed by extracting the desired properties (i.e. 
atomic positions, velocities, and forces as a function of time) to gain insights into protein 
function, conformational dynamics, correlated motions, hydrogen-bonding, water-mediated 
interactions, and secondary structure changes. The most common analyses performed on MD 
simulations are discussed below, each of which yields a time series of values derived from the 
trajectory. 
 
2.8.8.1 Root-mean-square deviation (RMSD) 
 The most commonly used quantitative measure of the similarity between two 
superimposed models is typically calculated by the root-mean-square deviation (RMSD):  
 
!"#$ = ! !! Σ!!!! !"! !– !!0! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!(Equation 2.27 RMSD) 
 
where ri represents the position at time i, r0 represents position at time 0, and  N represents the 
number of atoms. RMSD quantifies the deviation of a protein from the reference conformation as 
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a function of time. An optimal overlay can be based on all atoms overlapping or just the 
backbone, favoring a minimal RMSD overall. The RMSD can also be used as an indicator of 
convergence of the structure towards an equilibrium state. 
 
2.8.8.2 Root-mean-square fluctuation (RMSF) 
 The root-mean-square fluctuation (RMSF) is a measurement of the thermal motions of a 
residue that captures overall atomic fluctuations, offering insight into the flexible regions of a 
protein.  It is calculated by: 
 
!"#$! = ! !! Σ!!!! !! !−!< ! > !                                                    (Equation 2.28 RMSF) 
 
where ri represents the position at time i and is a selectable parameter that represents the atoms, 
backbone or any other subset, N represents the number of samples, and < r > represents the 
average value. Typically the reference position will be the time-averaged value of the same 
particle. 
 
2.8.8.3 Radius of gyration (Rg) 
 The radius of gyration (Rg) calculation provides an indication of the shape (compactness) 
of a protein as a function of time. It is directly connected to the folding nature of a protein. If a 
protein is folded, it will maintain a relatively steady value of Rg; if it unfolds, its Rg will change 
over time. The Rg is calculated by: 
 
!" = ! !! !! − !!!" !!                                                                        (Equation 2.29 Rg) 
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where ri - rcm is the distance between atom i and the center of mass, rcm of the molecule. Rg 
quantifies the overall compactness of a protein. 
 
2.8.8.4 Clustering 
 The data generated from MD simulations is quite extensive giving rise to a challenging 
analysis; therefore a method to identify conformational states, which are frequently and 
repeatedly populated, is necessary. Clustering analysis is a popular and widely utilized data-
reduction method that focuses on separating ensembles into groups of structures that share similar 
conformational features.267 Therefore the representative number of structures can then be utilized 
for subsequent analysis rather than the thousands of conformations generated in a typical 
simulation. The goal of clustering is to assign patterns to a particular group. The similarity 
measure between two conformations used in clustering is based on the Euclidean distance and is 
calculated by: 
 
!!" != ! !!,! !− !!!,!!!"#!!!                                                  (Equation 2.30 Clustering) 
 
 
where ωm,i is the value of torsion angle m in conformation i and Ntor is the total number of torsion 
angles. Clustering can lower the complexity of the structural information contained in the many 
conformations. When comparing conformations, the RMSD is calculated and a similarity matrix 
is built. There are a large number of cluster algorithms that belong to the following categories:  
1) hierarchal (top-down)  
2) linkage (bottom-up)  
3) Jarvis-Patrick   
4) refinement 
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The three most commonly used cluster algorithms are the GROMOS,268 linkage and 
Jarvis-Patrick269 methods. The GROMOS method268 utilizes the hierarchal (top-down) 
approach, where the neighbors of a structure are determined based on a given RMSD cut-off. The 
structure with the greatest number of neighbors is utilized as the center of the cluster and 
subsequently eliminated from the pool of structures. The process is repeated until the pool is 
empty. Clusters are mutually exclusive; therefore a structure can only be a member of a single 
cluster. The linkage method utilizes the bottom-up approach, where at the start of the analysis 
the data set contains as many clusters as conformations. Initially, all the inter-cluster distances are 
calculated between each pair of conformations. In each subsequent step, the closest pair of 
clusters merges into one until the closest pair differs by a predefined RMSD cut-off. The Jarvis-
Patrick method269 measures the distance between two objects and two integers, J and K, where J 
is the size of the neighbor list and K is the number of common neighbors. The nearest neighbors 
are determined for each object in the set to be clustered. Two conformations are assigned to the 
same cluster if: (1) the two conformations are within the cut-off distance and (2) they have the 
same number of nearest neighbors in common. 
 
2.8.8.5 Principal component analysis (PCA) 
 Another data-reduction and frequently utilized technique is principal component analysis 
(PCA).270-273 Conformational trajectories reside in high dimensional space containing information 
about all atomic coordinates. PCA is commonly used to reduce the dimensionality of a data set.250 
It can be used to calculate the directions and amplitudes of greatest motion along a simulation 
trajectory. In general, a principal component is a linear combination of the variables: 
 !! != ! !!,!!!!!!!                                                                                  (Equation 2.31 PCA) 
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with v variables, where pi is the ith principal component and ci,j is the coefficient of the variable 
xj. PCA is an orthogonal linear transformation that transforms a multi-dimensional data set into a 
reduced space spanned by principal components (PCs)273; thus highlighting principal motions or 
dominant features. It maps data sets of high dimensionality, for example, the vast vector space 
(V) spanned by the 3N coordinates of a simulation system, sampled across millions of times steps 
(the matrix, R) into a new vector set (V’), defined by an alternative basis set. The application of 
PCA involves computing the variance of the different variables in a data set and subsequently 
arranging the data in descending order. The first principal component (PC1) contains the most 
variance; the second (PC2) contains the second highest variance and so forth. PCA begins by 
removing the six rigid-body translational and rotational degrees of freedom of the molecule via 
least-squares structural superimposition of each frame to a reference (i.e. initial structure). The 
following steps express the transformation of a 3N x m matrix, R from 3N Cartesian coordinates 
at frames 1,2,…,m. PCA is then achieved in two steps: (1) by using R to construct the variance-
covariance matrix, C, of 3D coordinate displacements, ! versus the trajectory-averaged mean 
coordinates ! , and then (2) diagonalizing C to obtain the principal components of the motion as 
projections onto the eigenvector of the covariance matrix. 
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 A data set is introduced and centralized by computing the mean: 
 ! = ! !!,… , !!  
! = ! 1! !!!!!!  
(Equation 2.32 PCA Mean) 
 
 Construction of the variance-covariance matrix, C: 
 
(1) ! = !!! = ! ! ! − ! ! ! − ! ! ! 
 
(Equation 2.33 PCA variance covariance matrix) 
 
The covariance matrix diagonalized: 
 
(2) ! = !Λ!! 
(Equation 2.34 PCA matrix diagonalized) 
 
where Y is the orthogonal transformation of diagonalized matrix, Λ is diagonal matrix containing 
the corresponding eigenvalues (λ), and T denotes the transpose. 
 The solved eigenvalues are represented as: 
 !!! = !!!!!!                                                                     (Equation 2.35 PCA eigenvalues) 
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and placed in decreasing order from λ1 to λN . The eigenvectors correspond to the computed 
eigenvalues and are represented as: 
 ! = !!, !!,… , !!                                                        (Equation 2.36 PCA eigenvectors) 
 
Therefore, the original trajectory coordinates in the matrix R are transformed to a new 
coordinate system, which can be projected onto the eigenvectors (modes) in order to visualize the 
motion along teach of those directions giving the corresponding principal components. The use of 
PCA has been shown to be a reliable method to analyze protein-structure ensembles.274,275  
 !  
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Chapter 3: Structural mutation analysis of PTEN and 
its genotype-phenotype correlations in endometriosis 
and cancer 
 
3.1 Introduction 
 The phosphatase and tensin homolog deleted on chromosome ten (PTEN) gene encodes a 
tumor-suppressor phosphatase that has recently been found to be frequently mutated in patients 
with endometriosis, endometrial cancer, and ovarian cancer. Here, we present the first 
computational analysis of 13 somatic missense PTEN mutations associated with these 
phenotypes. We found that a majority of the mutations are associated in conserved positions 
within the active-site and are clustered within the signature motif, which contain residues that 
play a crucial role in loop conformation and are essential for catalysis. In silico analyses were 
utilized to identify the putative effects of these mutations. In addition, coarse-grained models of 
both wild-type (WT) PTEN and mutants were constructed using elastic network models to 
explore the interplay of the structural and global dynamic effects that the mutations have on the 
relationship between genotype and phenotype. The effects of the mutations reveal that the local 
structure and interactions affect polarity, protein structure stability, electrostatic surface potential, 
and global dynamics of the protein. Our results offer new insight into the role in which PTEN 
missense mutations contribute to the molecular mechanism and genotypic-phenotypic correlation 
of endometriosis, endometrial cancer, and ovarian cancer. 
The crystal structure of PTEN reveals two major domains: a lipid phosphatase domain 
that contains the catalytic active-site and a tightly associated C2 domain, which participates in 
membrane binding.4 The wall of the active-site pocket is delimited in part by the signature motif 
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P loop (H123CKAGKGR130), WPD loop (residues 88-98), and TI loop (residues 160-171) which 
contain residues that are responsible for catalysis (D92, C124, and R130), the overall positive 
charge within the active-site (H93, K125, K128), mediation of loop motion (H123 and G127), 
and govern the depth and width of pocket (4-residue insertion: K163, K164, G165, and V166).4 
The tumor suppressor function of PTEN is dependent on its phospholipid phosphatase activity 
and the loss-of-function of the phosphatase catalytic domain is commonly associated with 
oncogenic PTEN mutations.4,178-180 Recently, somatic mutations and deletions of PTEN have been 
reported in many types of sporadic tumors, including endometriosis, endometrial, and ovarian 
cancers.147,156,176,182-189,276  
Despite over three decades of research and significant understanding of endometriosis, 
the molecular mechanism and pathogenesis underlying its proliferation remains incompletely 
understood. The incidence of PTEN mutations in endometrium tissue of women diagnosed with 
endometriosis and endometrial hyperplasia is one of the highest among analyzed tumors and the 
most commonly mutated gene identified in endometrial cancer.169,182 Recent evidence suggests 
that endometrial and ovarian carcinomas are frequently found in association with endometriosis, 
suggesting that they arise through malignant transformation.50,126,147,156,187-189,276 Moreover, women 
with a history of endometriosis are also at an increased risk for developing cancer.126-129 These 
data suggest that a greater understanding of the complicated mechanism of endometriosis and 
malignant transformation will not only illuminate its molecular etiology, but may lead to both 
therapeutic development and early diagnostic methods.  
Insights into the catalytic properties of PTEN provide a platform to analyze the mutations 
found in endometriosis, endometrial cancer, and ovarian cancer. Recent computational studies on 
PTEN reveal that missense mutations affect its function and structure.192,193 Therefore a careful 
dissection of the effects of putative mutations is pertinent to understanding the molecular 
mechanism in each of the identified phenotypes. We analyzed thirteen somatic missense PTEN 
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mutations that were identified from published literature, and further validated them in the My 
Cancer Genome database277 as well as the Catalog of Somatic Mutations in Cancer (COSMIC) 
database.278 Our approach focuses on understanding the impact that these missense mutations 
have on the structure of PTEN and on investigating the molecular mechanism of each of the 
phenotypes.  
 
3.2 Computational methods 
3.2.1 PTEN somatic missense mutations dataset 
Somatic missense mutations for endometriosis, endometrial cancer, and ovarian cancer 
were taken from both the My Cancer Genome277 and the Catalogue of Somatic Mutations in 
Cancer (COSMIC) (version 49) databases278 and a comprehensive literature screening was 
conducted as listed in Table 3.1. A cut-off of 13 distinct missense mutations were chosen based 
on the highest percentage and frequency of the individual mutation somatic mutations found in 
the endometrium and ovaries as indicated in Table 3.2 and Figure 3.1.  
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Table 3.1 PTEN somatic missense mutations and phenotypes 
Mutations Phenotype Domain Reference 
p.G36R Endometrial Hyperplasia 
Ph
os
ph
at
as
e 
Maxwell et al., 1998;  
Minaguchi et al., 2001 
p.G36E Endometrial Cancer Dutt et al., 2008 
p.H123Y Endometrial Cancer Myers et al., 1997; Bonneau et al., 2000 
p.C124S Endometrial Cancer Kurose et al., 1998 
p.G129R Endometrial Cancer Risinger et al., 1997; Furnari et al., 1997 
p.G129E Endometrial Cancer Risinger et al., 1997; Weng et al., 2001 
p.R130G Endometrial Cancer Bonneau et al., 2000; Obata et al., 1998; 
Byron et al., 2008; Dutt et al., 2008; Oda 
et al., 2005; Minaguchi et al., 2001 
Endometriosis Willner et al., 2007 
Ovarian Cancer Lovly et al., 2015  
p.R130Q Ovarian Cancer Sampson 1925; Sainz de la Cuesta et al., 
1996; Saito et al., 2000; Castiblanco et al., 
2006; Mandai et al., 2009; Xu et al., 2011 
Lovly et al., 2015 
p.R130L Endometriosis Maxwell et al., 1998; Han et al., 2000; 
Obata et al., 1998 
p.R173C Endometrial Hyperplasia Maxwell et al., 1998; Risinger et al., 1998 
Endometrial Cancer Bussaglia et al., 2000; Minaguchi et al., 
2001; Dutt et al., 2008; Risinger et al., 
1998 
p.R173H Ovarian Cancer Sampson 1925; Sainz de la Cuesta et al., 
1996; Saito et al., 2000; Castiblanco et al., 
2006; Mandai et al., 2009; Xu et al., 2011 
p.V191A Endometrial Hyperplasia 
C
2 
Maxwell et al., 1998; Han et al., 2000 
p.T348I Endometrial Hyperplasia Maxwell et al., 1998; Georgescu et al., 
1999; Han et al., 2000 
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Table 3.2 Incidence of PTEN mutations in cancers 
Incidence of somatic missense PTEN mutations 
in human cancers 
  Percentage of tumors with 
mutation/number of samples 
  PTEN  
     
Primary Tumor Tissue Survey  % #  
     Prostate  1 658  
Breast   1 1198  
Endometrium  9 1837  
Cervix  0 413  
Vulva  6 18  
Soft Tissue  1 298  
Upper aerodigestive tract  1 777  
Biliary Tract  4 56  
Ovary  1 845  
Stomach  2 542  
Liver  1 380  
Kidney   1 474  
Pancreas  2 198  
Central Nervous System  4 3638  
Large Intestine  1 1114  
Meninges  1 170  
Eye  6 71  
Skin  1 768  
Thyroid  0 715  
 
 
  
!!65 
Figure 3.1 Distribution of PTEN somatic mutations in endometrium and ovaries  
 
 
3.2.2 Generation of PTEN structure mutants 
The wild-type (WT) structure of human PTEN protein crystallized with tartrate (TLA) 
(PDB ID 1D5R) was obtained from the Protein Data Bank (PDB).205 The tartrate molecule was 
removed and the calculations were conducted on apo PTEN. The mutant structures were built in 
silico by side chain replacement utilizing the Visual Molecular Dynamics (VMD) Mutator Plugin 
1.3207 starting from the WT PTEN (PDB ID: 1D5R) crystal structure file. Thirteen mutant 
structure models were generated for each of the phenotype mutations (p.G36E, p.G36R, 
p.H123Y, p.C124S, p.G129E, p.G129R, p.R130G, p.R130L, p.R130Q, p.R173C, p.R173H, 
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p.V191A, and p.T348I).  
Energy minimization was performed on each PTEN mutant structure using GROMACS 
4.6.3270 employing the GROMOS53a6 force field257 to remove possible steric clashes and 
minimize forces introduced as a result of the mutation. A series of five overall minimization 
stages were performed to remove any steric clashes and minimize the forces that were introduced 
as a result of the mutation that was introduced to the WT structure. Each PTEN mutant was 
subjected to a step-wise energy minimization using the steepest descent method. Step-wise 
energy minimization involved 5 steps: in step 1 all protein atoms were restrained, in step 2 
protein heavy atoms were restrained, in step 3 all protein atoms were restrained again, in step 4 
atoms of the protein main chain were restrained and in step 5, unrestrained energy minimization. 
Total minimization was carried out until convergence where the maximum atomic force was less 
than 1000 kJ/mol-nm. 
 
3.2.3 pKa prediction and electrostatic surface potential (ESP) 
calculations 
The single-site pKa predictions199,279-281 were carried out on WT PTEN (Apo) at pH 7 
using Chemistry at HARvard Molecular Mechanics (CHARMM),282 and University of Houston 
Brownian Dynamics (UHBD).202 The PTEN PDB entry 1D5R4, contains the atomic coordinates 
of the protein as required for calculation of pKa. The pKa input contained partial atomic charges 
and atomic radii for each atom, maximal number of iterations [300], ionic strength [150 mM], 
dielectric constant [solvent 80, protein 20], temperature [298K], and spacing [4: 3.0 45 45 45; 1.2 
15 15 15; 0.75 15 15 15; 0.25 20 20 20] in Angstroms.  
Upon completion of the pKa calculation of each ionizable residue, an electrostatic surface 
potential (ESP) map was generated.  Electrostatic interactions are long ranged interactions and 
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can accelerate the rate at which molecules associate.208 The ESP calculations were carried out for 
both WT PTEN and mutants using Adaptive Poisson-Boltzmann Solver (APBS).283  
 
3.2.4 Multiple sequence alignment (MSA) – sequence conservation 
The protein sequence of PTEN was searched against the UniProt284,285 sequence database 
to obtain homologous PTEN proteins sequences.  Multiple sequence alignments (MSA) were 
constructed utilizing CLUSTALW210 and manually inspected using Jalview.211  
 
3.2.5 Structural stability prediction 
I-Mutant 3.0 (http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi) 
is a support vector machine (SVM)-based tool that calculates protein stability changes upon 
mutation either from sequence or structural information.240 We utilized the structure-based 
version of I-Mutant 3.0, which classifies the prediction into one of three classes: neutral mutation 
(-0.5 ≤ ∆∆G ≥ 0.5 kcal/mol), large decrease (<-0.5 kcal/mol), or large increase (>0.5 kcal/mol).240 
The predicted free energy change, ∆∆G, is based on the difference between unfolding Gibbs free 
energy change of mutant and native protein (kcal/mol).240 CUPSAT (http://cupsat.tu-bs.de) is a 
physiochemical modeling program that utilizes a Boltzmann mean-force potential and torsion 
angles (phi, psi) to predict ∆∆G values and stability changes.241 CUPSAT also calculates the 
overall stability change as well as the adaptation (favorable or unfavorable) of the observed 
torsion angles (phi, psi) as a result of the mutation. The WT PTEN structure file (PDB ID 1D5R)4 
was utilized with the residue name and mutation site required as input.  
To explore the effects of the mutations on structure stability and dynamics we employed 
Elastic network contact model (ENCoM) (http://bcb.med.usherbrooke.ca/encom),242,243 that 
utilizes a novel mixed coarse-grained normal mode method to account for the type and extent of 
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pairwise atomic interactions allowing for the calculation of vibrational entropy differences as a 
result of mutations.242,243 ENCoM utilizes a potential function with four terms: (1) covalent bond 
stretching, (2) angle bending, (3) dihedral torsion, and (4) non-bonded interaction while taking 
into consideration the nature and possible effects that the orientation of the side-chains have on 
dynamics within the context of normal mode analysis. The WT PTEN structure file (PDB ID 
1D5R)4 was utilized with the residue name and mutation site required as input. 
 
3.2.6 Anisotropic network normal mode analysis (NMA) 
The anisotropic network model (ANM), is a coarse-grained model utilized to investigate 
protein dynamics and vibrational functional motions.225 Utilizing elastic network methodology 
(ENM), ANM calculations involved only Cα atoms and employed a uniform spring constant γ 
with a cut-off distance of 1.5 nm for interacting atoms, such that the overall potential of the 
system is a sum of harmonic potentials.223,286 Anisotropic displacements and intrinsic collective 
motions of WT and mutant PTEN structures were analyzed using ProDy287 to obtain the six 
slowest nontrivial normal modes.  
 
3.2.7 All-atom normal mode analysis (NMA) 
 All-atom normal mode analysis (NMA) was conducted on representative molecular 
dynamics (MD) simulations using GROMCAS 4.6.3270 with GROMOS53a6 force field257 on 
(apo) WT PTEN (PDB ID 1D5R) and mutants as a structural basis. Each system was solvated 
inside a cubic box of simple point charge (SPC)264 water with at least 10 Å of water between the 
protein and edges of the box. All simulations were performed in explicit solvent, with chloride 
(Cl-) counter ions added to obtain neutrality of the system. Periodic Boundary Conditions and a 2 
fs time step were employed for each simulation. Each system contained roughly 75,825 atoms. 
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The Particle Mesh Ewald (PME) method288 was used to treat long-range electrostatic interactions 
and a cutoff of 9 Å was used for non-bonded interactions. A series of five overall minimization 
stages were performed on each PTEN model to remove any steric clashes and minimize the 
forces that were introduced as a result of the mutation introduced to the WT structure. Each 
system was then subjected to a step-wise energy minimization using the steepest descent method. 
The minimized structures were then slowly heated from 0 to 300 K over 100 ps and equilibrated 
for an additional 250 ps. The system was heated to 300 K by linearly by increasing the 
temperature, through velocity rescaling, every 10 ps. The production runs were performed in the 
NPT (isobaric-isothermal) ensemble at 300 K. Bond lengths were constrained using LINear 
constraint solver (LINCS) algorithm261 and the van der Waals forces were maintained at 1.4 nm. 
The Berendsen266 weak coupling method was employed to maintain constant temperature with a 
temperature coupling relaxation time of 0.1 ps, a pressure coupling constant of 0.5 ps, and a 
compressibility of 4.5 ! 10-5. The total simulation time for each model was 200 ns and 
coordinates were recorded every 1 ps. Normal mode analysis of each system was conducted by 
performing principal-component analysis. Normalizing each eigenvalue of the covariance matrix 
to its total sum yields the percentage of all movements attributable to the corresponding 
eigenvector. The largest eigenvalues correspond to the principal-component modes that best 
explain the molecular motions sampled by the all-atom system trajectories. 
 
3.3 Results and discussion 
3.3.1 Mapping somatic missense mutations to PTEN structure 
To investigate the pattern of PTEN mutations in each of the phenotypes, we analyzed the 
prevalence of PTEN somatic missense mutations from data presented in literature over the past 
three decades. The spectrum of their associated phenotypes is shown in Table 3.1. Using the My 
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Cancer Genome and the Sanger COSMIC databases, PTEN was screened and the thirteen 
mutations were confirmed to be within the highest percentage of somatic mutations found in the 
endometrium and ovaries (Table 3.2 and Figure 3.1). Using these data, we investigated the 
functional impact of the mutations and whether any correlation exists between PTEN genotype 
and disease phenotype. 
The domain structure of the PTEN protein comprises a phosphatase domain (residues 1-
185) and a C2 domain (residues 186-351), which are both vital for tumor suppressor function. 
The phosphatase domain contains a tyrosine phosphatase signature motif (H123CKAGKGR130) 
that forms a P loop within the active-site pocket. Within this loop, the C124 and R130 residues 
are essential for catalysis. Knowledge of the catalytic mechanism provides a rational basis for 
understanding a number of the mutations reported within PTEN. Thus, we created a histogram, 
identifying mutational hotspots within the domain structures of PTEN to further highlight 
mutations surrounding the active-site that may affect catalytic activity and structural stability 
(Figure 3.2). We found the vast majority of mutations localized within the phosphatase domain, 
particularly the signature motif, suggesting that phosphatase activity is essential for the 
physiological function of PTEN in tumor suppression.  
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Figure 3.2 Mutation distribution within the domain structure of human PTEN 
 
 
To further examine the local structure and interactions around each mutated residue in 
both domains of PTEN, these mutations were mapped to the three-dimensional structure of PTEN 
as shown in Figures 3.3 A-B. We observed that nine mutations associated with severe 
phenotypes: six (p.H123Y, p.C124S, p.G129E, p.G129R, p.R130G, and p.R130Q) are clustered 
within the active-site pocket, one (p.G36E) is located near the N-terminus and two (p.R173C and 
p.R173H) are located at the phosphatase-C2 domain interface. Four of the thirteen mutations 
(p.G36R, p.R130L, p.V191A, and p.T347I) present mild phenotypes and are scattered throughout 
both PTEN domains (Figures 3.2 and 3.3 A-B). p.R173C is involved in both mild and severe 
phenotypes: endometrial hyperplasia, endometrial cancer, and ovarian cancers, respectively 
(Table 3.1).  
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Figure 3.3  Three-dimensional structure of PTEN and mutants 
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Residues C124 and R130 are affected by missense mutations and play significant roles in 
catalytic activity and protein function. Most importantly, R130 has mutations (R130G, R130L, 
and R130Q) implicated in each of the three phenotypes: endometriosis, endometrial cancer, and 
ovarian cancer (Table 3.1 and Figures 3.3A-B). These three distinct R130 mutations 
considerably change the size of the respective amino side chains such that the local structure and 
interactions might be disturbed. Three loops (WPD, P, and TI) that comprise the active-site 
pocket of the phosphatase domain are responsible for the overall positive charge (H93, K125, and 
K128), catalysis (D92, C124, and R130), mediation of loop motion (H123 and G127) and govern 
the depth and width of the pocket (K163, K164, G165, and V166) (Figure 3.3A).4  
Interestingly, the p.G129E mutation is found in patients with endometrioid tumors with 
high frequency.30,179 The position of this residue is located at the bottom of the active-site cleft 
near the TI loop that contributes to the extended active-site pocket (Figures 3.3A-B). Mutations 
p.G129E and p.G129R reduce the size of the catalytic pocket, thus hindering accommodation of 
the bulky phosphoinositol moiety of the substrate PIP3 (Figures 3.3A-B).4 This mutant likely 
retains protein tyrosine phosphatase (PTP) activity because the phosphorylated inositol head 
group requires a larger and shallower pocket.289 Additionally, the glycine is located in a 
conserved region and is essential at this position to adopt a backbone conformation needed to 
accommodate the phosphoinositol moiety and a mutation to glutamic acid thereby reduces the 
flexibility of the backbone (Figure 3.4). Substitution of arginine (p.G129R), which has a larger 
side chain than glutamic acid, results in complete loss of both protein tyrosine phosphatase and 
lipid phosphatase activities.289 It is possible that mutations involving the P, WPD, or TI loops 
disrupt the size and overall positive charge of the active-site pocket, the tumor suppressor 
function of PTEN, and thus contributes to the development of tumors with a more severe 
phenotype.290 
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3.3.2 PTEN sequence conservation 
Disease-causing mutations are typically located at conserved positions within a protein 
family since these residues are usually essential for the structure and/or function of the 
protein.291,292 Within PTEN, the P loop is highly conserved between species, whereas the WPD 
and TI loops are more divergent (Figure 3.4). The inter-domain interface residues of the 
phosphatase domain are second only to the P loop in conservation across species and those of the 
C2 domain are the best-conserved C2 regions (Figure 3.3A).4 The majority of the somatic 
missense mutations investigated in this study are located within a contiguous conserved cluster 
(Figure 3.2) formed around the active-site and highly conserved P loop as well as the inter-
domain region conferring significant phenotypic changes and can be targeted as potential hot-spot 
regions for the development of novel therapeutic agents in the treatment of endometriosis, 
endometrial cancer, and ovarian cancer. 
 
Figure 3.4 Multiple sequence alignment (MSA) of PTEN catalytic loops 
 
3.3.3 Structural and stability effects of PTEN mutations  
To understand the structural and phenotypic consequences of the missense mutations in 
PTEN protein, we utilized a combination of molecular modeling, structural analysis, and 
bioinformatics methods to analyze the identified mutations. The effects of the mutations reveal 
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that the local structure and interactions affect polarity, protein structure flexibility, and 
electrostatic surface potential. Structural analysis of p.H123Y, p.C124S, and p.R173H reveal that 
alterations in the residue size and hydrophobicity disturb the structure and disrupt hydrogen 
bonding (Figures 3.5A-D). The signature motif contained in the loop between pβ5-strand and α4-
helix includes two residues H123 and C124 essential for the conformation of the P loop and for 
catalysis, respectively. The mutation of H123 to tyrosine, causes a steric clash with Y76 
disrupting the π-π stacking between H123 with Y76 and F37 thus extending the pβ5-strand before 
the P loop (Figure 3.5A).  
 
Figure 3.5 Structure analysis of WT PTEN 
 
 
Basic residues H93, K125, K128, surround the catalytic C124 residue and R130, and 
hydrogen bonds with the side chains R130 and T131 (Figure 3.5B). The p.C124S mutation 
introduces a slightly less hydrophobic side chain disrupting the hydrogen-bonding interactions, 
lowering the pKa (Table 3.4) and presumably its ability to act as a nucleophile with its known 
substrate PI(3,4,5)P3. In fact, previous research has shown that p.C124S completely inhibits 
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PTEN’s lipid and protein phosphatase activity and was defective in phosphatase activity against 
PI(3,4,5)P3 and PI(3,4)P2.293,294 The p.R173H mutation disrupts inter-domain hydrogen bonding 
with W274 (2.2Å to 3.6Å) and imposes steric clash and side chain distortion with the nearby 
residue, V262 (Figures 3.5C, D). 
Individual missense mutations may destabilize a protein and impact its folding ability. To 
consider this effect and estimate the level of structural destabilization associated with each 
missense mutation, we predicted quantitative stability changes utilizing multiple programs that 
calculate the change of the protein structural stability induced by mutations (∆∆G). In order to 
provide points of comparison, we utilized multiple programs such as I-Mutant 3.0,240 Cologne 
University Proteins Stability Analysis Tool (CUPSAT),241 and Elastic Network Contact Model 
(ENCoM) (Table 3.3).242,243 I-Mutant 3.0 was utilized to calculate protein structure stability 
changes from the predicted free energy change (∆∆G) upon mutation as provided from either 
sequence or structural information.240 I-Mutant 3.0 predicts each of the thirteen mutations 
(p.G36R, p.G36E, p.H123Y, p.C124S, p.G129R, p.G129E, p.R130G, p.R130L, p.R130Q, 
p.R173C, p.R173H, p.V191A, and p.T348I) to be destabilizing presenting with negative free 
energy change (∆∆G) values -1.30, -0.94, -0.67, -1.12, -1.33, -1.03, -2.15, -0.56, -1.56, -1.57, -
1.71, -0.18, and -1.61 kcal/mol, respectively. Eight of these mutations (p.G36R, p.H123Y, 
p.G129E, p.G129R, p.R130G, p.R173C, p.V191A, and p.T348I) are in agreement with 
experimental data that suggests the loss of lipid phosphatase activity toward PIP3 as a result of the 
loss of stability in the protein. 
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Table 3.3 Predicted effects on protein stability (ΔΔG) for the 13 PTEN missense mutations 
 
 
 
I-Mutant 3.0 
 
CUPSAT (thermal) 
 
ENCoM 
Mutation 
ΔΔG 
kcal/mol 
Predicted 
Impact 
ΔΔG 
kcal/mol 
Predicted 
Impact 
Torsion 
Angle 
ΔΔG 
kcal/mol 
Predicted 
Impact 
p.G36E -1.30 Destabilizing +2.04 Stabilizing Unfavorable -0.54 Stabilizing 
p.G36R -0.94 Destabilizing -2.77 Destabilizing Unfavorable -0.91 Stabilizing 
p.H123Y -0.67 Destabilizing -2.13 Destabilizing Favorable -0.44 Stabilizing 
p.C124S -1.12 Destabilizing +3.09 Stabilizing Unfavorable -0.17 Stabilizing 
p.G129E -1.33 Destabilizing -2.30 Destabilizing Favorable -0.73 Stabilizing 
p.G129R -1.03 Destabilizing -2.83 Destabilizing Favorable -1.15 Stabilizing 
p.R130G -2.15 Destabilizing -2.21 Destabilizing Unfavorable +1.45 Destabilizing 
p.R130L -0.56 Destabilizing +0.66 Stabilizing Favorable +0.23 Destabilizing 
p.R130Q -1.56 Destabilizing +0.23 Stabilizing Favorable +0.27 Destabilizing 
p.R173C -1.57 Destabilizing -0.27 Destabilizing Unfavorable +0.53 Destabilizing 
p.R173H -1.71 Destabilizing +0.65 Stabilizing Unfavorable +0.12 Destabilizing 
p.V191A -0.18 Destabilizing -1.39 Destabilizing Unfavorable +0.32 Destabilizing 
p.T348I -1.61 Destabilizing -0.53 Destabilizing Unfavorable -0.86 Stabilizing 
The results of the structure web-based tools are in kcal/mol and negative (ΔΔG) energy change indicates 
that the mutation is predicted to destabilize the mutant PTEN structure, while positive (ΔΔG) energy 
suggests stabilization of the structure. 
 
 CUPSAT was utilized to predict protein stability changes upon single amino acid point 
mutation using structural environment-specific atom potentials and torsion angle (phi, psi) 
potentials. The predicted unfavorable torsion angles for the p.G36E, p.C124S, p.R130G, 
p.R130Q, p.R173C, p.R173H, p.V191A and p.T348I mutations could be the result of the inability 
of the torsion angles (phi, psi) to adapt to their new environment which contributes to the higher 
impact of the atom potentials on stability, thus resulting in a stabilizing mutant. The p.R130G 
mutation results in both a destabilizing mutation and unfavorable torsion angles due to the greater 
extent of flexibility forcing the backbone into an incorrect conformation that disturbs the local 
structure. 
Interestingly, the effect of these mutations on structural stability and dynamics can be 
further assessed with ENCoM in Figure 3.6. We chose ENCoM to predict the effect of mutations 
as it accounts for side-chain and long-range interactions offering a more realistic representation of 
intramolecular interactions. The p.R130G/L/Q, and p.R173C/H mutants have an increase in 
dynamics across the phosphatase-C2 domain interface. It has been previously posited that a 
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majority of mutations within the active-site pocket exhibit a loss of phosphatase activity as a 
result of the p.R173C/H mutations, further implicating this region as a possible mutation-driven 
allosteric interface. R173 forms a salt-bridge with D324 stabilizing the rich hydrogen bond 
network within the interface. Mutations located at position 173 result in a loss of charge and are 
involved in the destruction of this salt-bridge thus impairing the structural stability within the 
domain interface, contributing to a severe phenotype. This further highlights that the integrity of 
the interface is important for the overall stability of PTEN and these mutations could disrupt the 
global dynamics of the protein.  
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Figure 3.6 Effect of PTEN mutations on structural stability and dynamics 
 
 
To identify the overall sequence tolerance or effect that other amino acids impose at the 
13 identified positions, a heatmap was generated utilizing ENCoM, which calculates the ∆∆G 
distribution of the 20 essential amino acids for each of the given thirteen mutation positions 
(Figure 3.7). This heatmap allows the identification of hotspots throughout PTEN that affect 
structural stability. This is crucial as pathogenic mutations leading to monogenic diseases reveals 
a relationship between the destabilizing effects of mutations and severity of disease by as little as 
1–3 kcal/mol.  Additionally, since the evolution of a gain-in function or even a loss-in-function 
will be driven by a mutation of amino acids in key positions which may hinder interactions that 
ensure the stability of PTEN’s fold to the degree that it renders the protein non-functional. Of the 
13 mutations, positions G36, H123, C124, R130, and R173 possessed the largest stability 
decreases across the majority of the 20 amino acids. Conversely, positions G129, V191, and T348 
indicated an increase in stability across half of the 20 amino acids. These data provide further 
understanding of the effect of mutations and the phenotypic consequences at these positions.  
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Figure 3.7 PTEN mutation heatmap 
 
 
3.3.4 Correlated motions and effects of PTEN mutations on global 
dynamics 
To understand how the intrinsic and global dynamics are impacted by each of the 
missense mutations on PTEN, elastic network models and normal mode analysis were utilized. 
To achieve this goal, we utilized the ProDy software package287 for the construction of 
anisotropic network225 coarse-grained models of both WT PTEN and mutants to further explore 
the interplay of the structural and dynamic effects each of the mutants have on the global 
dynamics of the tertiary structure. Correlation between collective modes was predicted by the 
calculation of the anisotropic normal mode (ANM) for each of the WT and mutant models. Lower 
frequency modes contribute to the covariance and entail the most cooperation and largest 
amplitude motions. ANM analysis exhibited a high cumulative involvement coefficient for the 
first 10 slow modes. The mode which emphasizes the contribution of the slowest modes and 
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contributes the most to the overall global motions of each model is mode 2 which has the lowest 
nonzero “frequency” and involvement coefficient of CI2=1.00 best describing the conformational 
changes between the WT and mutant models. !
Additionally, though pairwise cross-correlations of the residue fluctuations of the first 
lowest eigenvectors (first three modes) are quite similar, the P loop and WPD loop regions were 
the most flexible in ANM mode 2. Therefore, of the 10 slowest nontrivial normal modes that 
were analyzed, ANM mode 2 revealed the greatest differences in the motions of WT and mutant 
models of PTEN. These ANM 2 modes were found to describe variations of “hinge-bending” and 
“zipper-lie” global movements, thus characterizing their global conformational changes and 
cooperative motions relative to their mutation (Figure 3.8A-N). 
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Figure 3.8 Global motions of WT PTEN and mutants 
 
 
Furthermore, to better discriminate the effects induced by each of the mutations on the 
protein structure, an all-atom normal mode analysis was conducted by calculating principle 
component analysis on molecular dynamics trajectory ensembles of the WT and mutant models. 
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The projections of the displacement described by the first principle components on the simulated 
frames were analyzed. The first principal component of each WT and mutant model collectively 
account for more than ~40% of the total motion and is therefore a suitable approach to analyze 
protein dynamics. The introduction of a large charged residue (p.G36E/R) causes both local 
effects on the N-terminal region and the C2 domain (Figures 3.9B,C). 
 
Figure 3.9 Protein dynamics fingerprint of WT PTEN and mutants 
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 The p.H123Y, p.C124S, and p.G129E mutations (Figures 3.9D-F) significantly affect the 
principal motions of the TI loop and are somewhat close to the WT fingerprint, whereas the other 
mutations have well-defined dynamic effects. Additionally, the p.C124S mutation (Figure 3.9E) 
has dramatic effects on the N-terminal region and the catalytic loops as well as the CBR3 loop in 
the C2 domain indicating this mutation induces long-range perturbations.  The p.G129R mutation 
(Figure 3.9G), though somewhat similar to p.G129E, has slightly more fluctuation to its principal 
motions most particularly in the N-terminal region and CBR3 loop. The p.R130G/L/Q mutations 
(Figures 3.9H-J) significantly alter PTEN dynamics in the surrounding active-site as well as 
long-range perturbations mostly due to the fact that the R130 position is catalytic. 
Interestingly, p.R173C/H mutations (Figures 3.9K,L) affect the principal motions of the 
P, WPD, and TI loops in the active-site, and the inter-domain interface, illustrating long-range 
perturbations. The p.V191A mutation (Figure 3.9M) exhibits dynamic patterns similar to 
p.C124S and p.R130L indicating that this mutation affects the global dynamics of the TI loop in 
the active-site as well as the CBR3 loop. Lastly, T348I mutation (Figure 3.9N) reveals principal 
motions similar to H123Y indicating that this mutation greatly affects the global dynamics of the 
P, WPD, and TI loops in the active-site.  Overall, each of the mutation motions captures the 
differences in the global dynamics induced by the effects of each mutation and reveal unique 
long-range perturbations within the PTEN protein.   
 
3.3.5 Effects of ionization states on PTEN mutations  
To understand whether the ionization states of titratable groups are affected by missense 
mutations, pKa calculations were predicted. pKa predictions provide insight into the local 
environment of critical residues within the active-site where the majority of the mutations are 
clustered (Table 3.4). The pKa predictions were performed on the apo form of PTEN using the 
1D5R structure without the TLA substrate. Thus, the apo conformation exposes the active-site 
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and was treated with a high dielectric constant of water.  Figure 3.10 illustrates interactions 
between WT PTEN ionizable residues and the tartrate molecule within the active-site. The pKa 
can shift depending on the surrounding environment thus affecting protein stability and activity.  
 
Table 3.4 PTEN WT pKa calculations 
Residue pKa Expected pKa Observed pKa Delta 
D92 4.00 -2.71 -6.72 
H93 6.30 5.93 -0.37 
D115 4.99 6.57 2.57 
H123 6.30 4.59 -1.71 
C124 8.30 3.79 -4.51 
K125 10.50 >>pH >>pH 
K128 10.50 8.94 -1.56 
R130 12.40 >>pH >>pH 
pKa calculations were performed with wild-type 1D5R structure 
without substrate. The pKa of the catalytic residue C124 showed 
a substantial shift toward greater acidity, which is attributable to 
the surrounding high density of basic residues. 
 
Figure 3.10 PTEN active-site with tartrate molecule 
 
The pKa of D92 was substantially shifted toward greater acidity due to the formation of 
hydrogen bonds with H93 and K125, thus stabilizing the deprotonated state. H93 is critical for the 
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affinity of negative substrates thus a moderate shift of 5.93 is critical to maintain the catalytically 
competent protonation state of the residue. The elevated pKa value of D115 is attributable to 
hydrogen-bond formation with basic residues R130 and K125, serving as a hydrogen-bond 
acceptor. The pKa of H123 is slightly depressed due to hydrogen-bond formation with Y76, and 
disruption of this hydrogen bonding in the p.H123Y mutation leads to destabilization of the 
protein (Table 3.3). C124 exhibits a substantial shift toward greater acidity, which is attributable 
to the surrounding high density of basic residues H93, K125, K128, and R130 (Figure 3.10) 
indicating that cysteine is stabilized in its thiolate form at physiological pH. A mutation from 
cysteine to serine would disrupt the electrostatic environment thus further perturbing the pKa.  
 
3.3.6 Electrostatic effects of PTEN mutations  
Electrostatic surface potential calculations were generated for WT PTEN and mutants. As 
expected, WT PTEN (apo) is predicted to have a highly positive electrostatic potential 
surrounding the active-site (Figure 3.11). Mutations within the active-site: p.H123Y, p.R130G, 
p.R130Q, and p.R130L reduce positive charge resulting in less favorable electrostatic, binding, 
and specificity interactions with PIP3, thus contributing to a severe phenotype. The introduction 
of a large charged carboxylate side chain for buried mutations: p.G36R, p.G36E, p.G129R, and 
p.G129E imposes backbone conformational constraints, the inability to facilitate loop movement, 
and exposure to solvent. More specifically, the p.G129E mutation would thus experience 
electrostatic repulsion when binding to PIP3 (Figure 3.11). The p.R173C/H mutations replace a 
large residue (R) with smaller ones (C/H), causing a loss in charge while disrupting the inter-
domain hydrogen-bond network (Figures 3.5C,D and 3.11).  
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Figure 3.11 Electrostatic surface potential of WT PTEN and mutants 
 
 
Altogether, our observed predictions correlated with a decrease in protein structure 
stability in each of the associated mutations. I-Mutant 3.0 predicts all 13 mutations to be 
destabilizing. ENCoM predicts six mutations, (p.R130G/L/Q, p.R173C/H, and p.V191A) to be 
destabilizing. The effect of these mutations on structural stability and dynamics were further 
assessed in Figures 3.6-3.9. Our results indicate that the p.R130G/L/Q and p.R173C/H mutants 
have an increase in dynamics across the phosphatase-C2 domain interface. We predict that 
mutations at position 130 that result in a change in polarity or charge would result in a reduction 
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in structural stability, thus, likely impairing the ability to participate in the catalytic mechanism. It 
is possible that altering WT interaction of this active-site residue would affect PTEN function and 
thus lead to severe phenotype. The loss of positive charge at the R130 position (Figure 3.11) as 
well as interaction with neighboring essential catalytic residues C124 and D92 would disrupt 
overall function of PTEN. 
The normal catalytic mechanism involves D92 donating a proton to the bridging oxygen 
of its substrate PIP3.27 Subsequently, R130 binds to the D3-phopsphate of PIP3 and transfers it to 
neighboring C124; this interaction is possibly lost due to mutations at position 130.27 Previous 
studies indicate that mutations within the active-site pocket, in addition to p.R173C/H mutants, 
exhibit inactivated phosphatase activity,6,181,289,295 revealing a possible long-range communication, 
further implicating this region as a possible mutation-driven allosteric interface. R173 forms a 
salt-bridge with D324 stabilizing the rich hydrogen bond network within the interface. We predict 
that mutations at position 173 that result in a loss of positive charge would invoke the destruction 
of this salt-bridge thus likely to impair the structural stability within the domain interface leading 
to a severe phenotype. This further emphasizes that the integrity of the interface is important for 
the overall stability of PTEN and that these mutations could disrupt the global dynamics of the 
protein. In CUPSAT, eight mutations (p.G36R, p.H123Y, p.G129E, p.G129R, p.R130G, 
p.R173C, p.V191A, and p.T348I) are predicted to be destabilizing. This is in agreement with 
experimental data that suggests the loss of lipid phosphatase activity towards PIP3 as a result of 
the loss of stability in the protein. The evolutionary-conservative analysis indicated that the 
majority of the disease-associated mutations are located in highly conserved parts of the PTEN 
structure (P loop as well as inter-domain region) (Figure 3.4). Our most notable observation was 
the identification of the inter-domain disruption caused by the mutations at positions 130 and 173 
that lead to the most dramatic effect on PTEN long-range communication with the protein and its 
overall function implicating a rather interesting interplay between these two positions that may be 
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involved in a potential mutation-driven allosteric interface. This provides motivation for future 
studies to further investigate a network of interactions that contribute to a possible allosteric 
signal transmission and long-range communication. It is known that PTEN plays a key role as a 
tumor suppressor protein and is involved in a variety of cellular functions and protein-protein 
interactions.296 Therefore, any significant changes in structural stability will modify the overall 
function of the protein having a global impact on various pathways involved in tumor suppression 
regulation. 
Our results suggest that the replacement of cysteine with serine would greatly alter the 
dynamics of the N-terminal region, catalytic loops, as well as the CBR3 loop affecting membrane 
binding, indicating this mutation induces long-range perturbations (Figure 3.9). The p.G129R 
mutation introduces a larger, positively charged residue into a highly conserved region that 
destabilizes the structure and thereby contributes to a more rigid P loop (Figure 3.9). The 
flexibility of the native glycine residue may be necessary for PTEN’s function. Additionally, 
mutations p.C124S, p.G129E, and p.R130G alter the polarity and charge of the active-site, 
leading to structural instability and a catalytically inactive mutant. Interestingly, recent 
experimental research implicates mutations p.C124S and p.G129E as contributing to a more 
severe phenotype, providing evidence that these inactive mutants disturb the function of co-
expressed WT protein and perhaps aggravate normal cellular behavior.297 Conversely, mutants 
retaining partial loss of function associate more frequently with a milder phenotype,297 this may 
also explain the mild phenotype seen in p.G129R as well as in the diverse range in severity of 
phenotype (from mild to severe) as seen in multiple mutations at one position as in p.G36R/E, 
p.R130G/L/Q, and p.R173C/H as investigated in this study. 
It is important to note that missense mutations at position 130 (p.R130G, p.R130L, 
p.R130Q) are located within the phosphatase domain of the active-site and participate in catalytic 
activity. Recently, p.R130G was identified as belonging to multivariate PTEN mutations 
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associated with endometrial cancer.290,298 Our results demonstrate position 130 to be involved in a 
potential long-range communication pathway with position 173. Additionally, in comparison to 
WT PTEN, we observed changes in overall global dynamics due to each of the R130 mutations 
(Figures 3.6-3.9). In the coarse-grained normal mode analyses, the R130 mutants revealed a 
“hinge-like” motion compared to the “scissor-like” motion of the WT PTEN (Figure 3.8). 
Whereas in the all-atom normal mode analysis of the principal components on the molecular 
dynamic ensembles, we see not only local effects on the active-site induced by the mutations but 
also disruption of the inter-domain and long-range perturbations. 
Previous studies reveal that the majority of the mutations within the active-site pocket 
exhibit a loss of phosphatase activity in addition to the p.R173C/H mutants located within the 
inter-domain interface (Table 3.1). Mutation p.R173C is experimentally predicted to reduce 
PTEN’s catalytic activity towards PIP3 substrate181 and thus its function as well. In many 
instances mutations affecting catalytic sites or protein interaction sites in general, can be sensitive 
to residue mutations distant from the active-site.299  Our results predict that both p.R173C and 
p.R173H destabilize the structure and disrupt the inter-domain interface (Table 3.3) (Figures 
3.5C-D and 3.6-3.9). These mutations are located within a buried hydrophobic core and a rich 
hydrogen-bond network, given this region is also highly conserved and integral to the hydrogen-
bond network, it further confirms the extreme importance of this interface for the PTEN function. 
Mutations at position R173 have been found mutated in a variety of cancers and is recognized as 
being among one of the eight most frequently mutated residues of PTEN.4 
In fact, within the COSMIC database alone, PTEN mutations at positions 130 and 173 are 
distinctly prevalent in endometrial, ovarian, and central nervous system tumors with a high 
frequency of position 130 mutations in endometrial and ovarian tumors, whereas only 4% of 
central nervous system (CNS) tumors also occur at this position. Additionally, 18% of CNS 
tumors correspond to position 173 with high frequency. We observed that mutations 
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p.R130G/L/Q and p.R173C/H have an increase in dynamics across the phosphatase-C2 domain 
interface and lead to a more severe phenotype (Figures 3.6-3.9).  
The missense mutations studied within this work allowed for perturbation of the WT 
properties of PTEN and provided a unique insight into two molecular mechanisms involving 
mutations at R130 and R173. Though genotype-phenotype correlations of these mutations are not 
solely attributable to a destabilization in structure, they are a major causative factor in 
endometriosis, endometrial cancer, and ovarian cancer as highlighted in this research. 
 
3.4 Conclusions 
Our results are not aimed at predicting the definitive value of the ΔΔG changes for each 
of the missense mutations but rather to gain insight into the stabilizing or destabilizing effects 
they have on the overall structure of PTEN. The majority of the somatic missense mutations 
investigated in this study are located within a contiguous conserved cluster (Figure 3.2) formed 
around the active-site and highly conserved P loop as well as the inter-domain region inducing 
structural instability and thus significant phenotypic changes. Ultimately, the primary goal was to 
investigate the genotype-phenotype relationship for each of the missense mutations presented in 
order that our results could be utilized to develop a more definitive diagnosis protocol and to this 
end, develop novel therapeutics for treatment of endometriosis, endometrial cancer, and ovarian 
cancer.   !  
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Chapter 4: Inter-domain communication pathway 
mechanism and correlated motions in endometriosis 
and cancer – associated PTEN mutations 
 
4.1 Introduction 
 Phosphatase and Tensin Homolog (PTEN) encodes a tumor suppressor protein that 
constitutes the main node of inhibition in the PI3K-Akt signaling pathway. Its most relevant 
function as a lipid phosphatase is based in its ability to catalyze the dephosphorylation of the 3’ 
phosphate of the inositol ring in phosphatidylinositol (3,4,5)-triphosphate (PIP3), an important 
intracellular lipid second messenger, thus restraining downstream anti-apoptotic and growth 
stimulatory effects that otherwise lead to unrestricted cell growth and tumorigenesis.4,6,7 
Alterations in the PI3K-Akt pathway give rise to various syndromes, metabolic dysfunctions, and 
cancer. We investigate the inter-domain communication pathway between both domains utilizing 
all-atom molecular dynamics (MD) simulations, communication pathway network analysis, and 
normal mode analysis. Communication network analysis was utilized to determine communities 
of residues that are critical to structural communication changes. Additionally, analysis of the 
residual local frustration and normal mode analysis of apo-and active-site bound (PIP3-PTEN) are 
utilized to discern correlated motions associated with wild-type and cancer-associated PTEN 
mutations. We find that certain residues play a critical role in controlling salient inter-domain 
communication pathways and motions that contribute to both subtle structural changes as well as 
global correlated motions that are essential to the function of PTEN. The results elucidate a 
network mechanism that involves correlated loop motions that affect protein dynamics offering 
novel insights into the potential correlation of endometriosis and cancer-associated PTEN 
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mutations. PTEN has recently been implicated in the malignant transformation of endometriosis, 
endometrial, and ovarian cancers.50,127,130,144-156 
Endometriosis is a gynecological disease that affects over 176 million women worldwide 
and is defined as the presentation of endometrial tissue outside (ectopic) the uterine cavity.121 
PTEN somatic missense mutations and deletions have been reported in endometriosis, 
endometrial and ovarian cancers.147,156,176,182-189,276 Clinically, endometriosis has been identified in 
~30% of cases with synchronous endometrioid type endometrial and ovarian cancers.155,162-164 The 
inactivation of PTEN is an early event in the premalignant lesion known as endometrial 
hyperplasia, which leads to the development of ovarian and endometrial cancers.169,176,191 Thus, 
somatic missense mutations may contribute to the genesis and development of endometriosis and 
subsequently cancer. The somatic missense mutations investigated here within, result from the 
analysis of our recent work identifying two potentially allosterically-driven mutation positions 
involved in all three of the aforementioned phenotypes.300 These two positions are also frequently 
mutated in PTEN in various disorders and cancers such as glioblastoma,301-304 Autism Spectrum 
Disorder,295 and Anaplastic Astrocytoma.305 Figure 4.1 demonstrates the distribution and location 
of PTEN somatic missense mutations retrieved from the COSMIC database.278 Therefore, a 
greater understanding of the effects of these mutations will offer insight into the disease 
mechanism and malignant transformation of endometriosis.  
 
  
!!94 
Figure 4.1 Location and frequency of PTEN missense mutations 
 
 
Structurally, PTEN consists of 403 amino acid residues which comprise two main 
domains: an N-Terminal phosphatase domain containing a central five-stranded β-sheet with six 
α-helices (two α helices on one side and four on another) wherein the active-site is delimited in 
part by three critical loops (P loop, WPD loop and TI loop) and a C-Terminal C2 domain that 
regulates membrane-binding which contains a β-sandwich that consists of two antiparallel β-
sheets with two short α helices intervening between the strands.4 The phosphatase and C2 
domains associate across an extensive inter-domain interface that is adjacent to the active-site and 
consists of conserved residues frequently mutated in cancer.4 The interactions of these two 
domains are controlled by three loops located in the catalytic active-site pocket, two (the P loop 
and WPD loop) of which share homology with both tensin and auxilin proteins that are 
commonly found in the regulatory sites of PTPs and DSPs. The phosphatase domain however 
contains a rather wide and deep catalytic pocket specific only to PTEN and is ~8 Å deep with an 
elliptical opening of ~5 x 11 Å.4 The extension and larger width of the active-site pocket is due to 
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the four-residue insertion of the TI loop. The flexibility of the WPD loop is required to adopt a 
closed conformation bringing the catalytic Asp92 closer to PIP3 enabling catalysis. The WPD 
loop also plays a similar role in the Yersinia protein tyrosine phosphatase (YopH) which is 
essential to the dynamics of the active-site.306 Mutations in the TI loop (T167), WPD loop (H93 
and D92), and P loop (C124, K128, G129, and R130) lead to a reduction in PIP3 phosphatase 
activity by ~75%.4  
Two additional motifs that also contribute to PTEN’s function and stability include: (i) 
the CBR3 loop (residues 260-269), and (ii) two ATP-binding motifs (residues 60-73 and 122-
136) the latter of which overlaps the P loop. The CBR3 loop facilitates membrane binding, which 
results in conformational changes that occur in the active-site leading to the assumption of an 
allosteric-activation mechanism in PTEN.293,307-310 Interestingly, previous studies have revealed 
that a slight conformational change in PTEN exposes both ATP-binding regions; however, a more 
substantial conformational change would essentially preclude its activity as a phosphatase 
establishing the existence of a role not previously described for this tumor suppressor.9,10,311  
Moreover, a more recent study utilizing neutron scattering combined with all-atom MD 
simulations revealed the importance of the CBR3 loop in membrane and active-site interactions 
with phosphatidylinositide substrates (PI(4,5)P2 and PI(3,4,5)P3).312 These inositolphosphates 
bind stronger to the protein in the absence of PIPs bound within the membrane.312 Additionally, a 
cluster of contacts of accumulated PI(4,5)P2 was observed at the C2 domain, which populated the 
CBR3 loop and the cleft (inter-domain) between the phosphatase and C2 domains (Figure 4.2). 
These results further implicate the importance of the CBR3 loop in the inter-domain dynamics as 
well as the communication pathway. 
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Figure 4.2 Structure of potential PTEN allosteric inter-domain area 
 
 
Recently we identified an inter-domain disruption within PTEN caused by mutations at 
positions R130 and R173 with an increase in dynamics across the phosphatase-C2 domain 
interface.300 Mutations at these two positions illustrated the most dramatic effect on PTEN long-
range communication within the protein suggesting an interesting interplay of their involvement 
in a potential mutation-driven allosteric interface (Figure 4.2). The combined structural and 
normal mode analyses led us to hypothesize that the inter-domain interface allows allosteric 
regulation between the phosphatase and C2 domain via global conformational changes among the 
mutant residues; therefore linking the inter-domain interface with the phosphatase active-site. 
This offers fresh insight into an association between PTEN long-range communication and inter-
domain allostery. Though traditionally, allostery has been defined as occurring between subunits 
in a multi-subunit system driven by a conformational change,313 a new concept of allostery has 
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been established suggesting that it may occur without a conformational change,314-316 and that all 
proteins may be capable of being allosterically regulated. 
Despite the specific nature of PTEN’s functional dynamics, the intra- and inter-protein 
conformational changes that govern its potential allosteric signal propagation have yet to be 
investigated and thoroughly defined. Moreover, missense mutations may have underlying effects 
on communication pathways that govern global conformational dynamics,317,318 inter-domain 
destabilization effects,319,320 propagation of allosteric signals,318 and correlated mutations involved 
in pathways of allosteric communication,318,321 all of which have yet to be identified within 
PTEN. Interestingly, missense mutations often occur at sites having a high local or global 
centrality in the protein structure network which are enriched by three-fold at the interaction 
interfaces of proteins associated with the various diseases.322 
Our previous findings set the stage for the present work, which is a more direct 
investigation of PTEN inter-domain communication. In particular, a necessary hypothesis, for our 
mutation-driven allosteric hypothesis is that the missense mutations associated with 
endometriosis, endometrial, and ovarian cancers, should alter the internal atomic properties of the 
active-site and inter-domain interface pertinent to binding.  To investigate this, we combined all-
atom MD, PSN-ENM-NMA, and analysis of residual local frustration to further explore the 
effects missense mutations have on dynamics of PTEN with a particular interest in changes that 
occur within the active-site and inter-domain interface. Specifically, we have generated in silico 
R130G, R130L, R130Q, R173C, and R173H mutants. This combined approach allows us to 
analyze the long-range communication within PTEN and associated mutants of the endometriosis, 
endometrial, and ovarian cancer phenotypes. Our choice of the mutants, derives from the high 
frequency association of endometriosis and cancer at positions 130 and 173 with each of the 
aforementioned phenotypes as well as our previous structural studies of PTEN.300 As indicated in 
the PTEN crystal structure (PDB ID 1D5R), mutations R130G/L/Q, are located within the P loop 
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of the active-site, adjoining the inter-domain interface where mutations R173C/H reside within 
the extensive hydrogen-bonding network (Figure 4.2 and 4.3).4 
 
Figure 4.3 PTEN inter-domain interface 
 
Inter-domain interface of PTEN with the interface residues highlighted in green licorice. 
 
4.2 Computational methods 
4.2.1 Molecular dynamics (MD) simulations 
4.2.1.1 System set-up 
 The 2.1 Å X-ray crystal structure atomic coordinates for wild-type (WT) PTEN were 
obtained from the protein data bank [PDB ID: 1D5R].4 The substrate-like tartrate (TLA) molecule 
was removed from the active-site for the apo-PTEN and mutant PTEN calculations.  All 
simulations were performed using GROMCAS 4.6.3270 with GROMOS53a6 force field257. Each 
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system was solvated inside a cubic box of simple point charge (SPC)264 water with at least 10 Å 
of water between the protein and edges of the box. All simulations were performed in explicit 
solvent, with chloride (Cl-) counter ions added to obtain neutrality of the system. Periodic 
Boundary Conditions and a 2 fs time step were employed for each simulation. Each system 
contained roughly 75,825 atoms. The Particle Mesh Ewald (PME) method288 was used to treat 
long-range electrostatic interactions and a cutoff of 9 Å was used for non-bonded interactions. 
 
Figure 4.4 Representation of PTEN simulation box with water molecules and chloride ions 
 
 
4.2.1.2 Energy minimization 
A series of five overall minimization stages were performed on each PTEN model to 
remove any steric clashes and minimize the forces that were introduced as a result of the mutation 
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that was introduced to the WT structure. Each system was then subjected to a step-wise energy 
minimization using the steepest descent method. 
 
4.2.1.3 Equilibration and production simulation 
 The minimized structures were then slowly heated from 0 to 300 K over 100 ps and 
equilibrated for an additional 250 ps. The system was heated to 300 K by linearly by increasing 
the temperature, through velocity rescaling, every 10 ps. Harmonic position restraints were 
applied to all heavy protein atoms in x, y, z dimensions (fx, fy, fz) starting from 1000 kJ/mol/nm2 
and gradually releasing to 0 kJ/mol/nm2. The production runs were performed in the NPT 
(isobaric-isothermal) ensemble at 300 K. Bond lengths were constrained using LINear constraint 
solver (LINCS) algorithm261 and the van der Waals forces were maintained at 1.4 nm. The 
Berendsen266 weak coupling method was employed to maintain constant temperature with a 
temperature-coupling relaxation time of 0.1 ps, a pressure-coupling constant of 0.5 ps, and a 
compressibility of 4.5 ! 10-5. The total simulation time for each model was 200 ns and 
coordinates were recorded every 1 ps.  
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Table 4.1 PTEN MD simulations 
System WT C124S G129E G129R R130G R173C R173H 
CPUs 240 
(146 
ns/day) 
128 
(113 
ns/day) 
128 
(114 
ns/day) 
128 
(105 
ns/day) 
128 
(117 
ns/day) 
128 
(112 
ns/day) 
128 
(116 
ns/day) 
Residues 307 307 307 307 307 307 307 
Water 
Molecules 
24,139 
(72,417 
atoms) 
24,140 
(72,420 
atoms) 
24,138 
(72,428 
atoms) 
24,138 
(72,414 
atoms) 
24,142 
(72,426 
atoms) 
24,137 
(72,411 
atoms) 
24,143 
(72,429 
atoms) 
Total 
Atoms 
75,829 75,830 75,837 75,837 75,823 75,811 75,835 
Total Cl- 
Atoms 
12 11 10 12 10 10 10 
Total Net 
Charge 
+12 +11 +10 +12 +10 +10 +10 
EM 
(Steepest 
Descent) 
until 
convergence 
until 
convergence 
until 
convergence 
until 
convergence 
until 
convergence 
until 
convergence 
until 
convergence 
EQ NVT 200 ps 200 ps 200 ps 200 ps 200 ps 200 ps 200 ps 
EQ NPT 150 ps 150 ps 150 ps 150 ps 150 ps 150 ps 150 ps 
Production 
Run 
787 ns 200 ns 200 ns 200 ns 200 ns 200 ns 200 ns 
 
System G36E G36R H123Y R130L R130Q V191A T348I 
CPUs 128 
(111 
ns/day) 
128 
(117 
ns/day) 
128 
(116 
ns/day) 
128 
(117 
ns/day) 
128 
(114 
ns/day) 
128 
(106 
ns/day) 
128 
(116 
ns/day) 
Residues 307 307 307 307 307 307 307 
Water 
Molecules 
24,133 
(72,339 
atoms) 
24,130 
(72,390 
atoms) 
24,135 
(72,405 
atoms) 
24,139 
(72,417 
atoms) 
24,140 
(72,420 
atoms) 
24,136 
(72,408 
atoms) 
24,138 
(72,414 
atoms) 
Total 
Atoms 
75,813 75,813 75,819 75,818 75,824 75,816 75,824 
Total Cl- 
Atoms 
10 12 11 10 10 11 11 
Total Net 
Charge 
+10 +12 +11 +10 +10 +11 +11 
EM 
(Steepest 
Descent) 
until 
convergence 
until 
convergence 
until 
convergence 
until 
convergence 
until 
convergence 
until 
convergence 
until 
convergence 
EQ NVT 200 ps 200 ps 200 ps 200 ps 200 ps 200 ps 200 ps 
EQ NPT 150 ps 150 ps 150 ps 150 ps 150 ps 150 ps 150 ps 
Production 
Run 
200 ns 200 ns 200 ns 200 ns 200 ns 200 ns 200 ns 
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4.2.2 Convergence and analysis 
 
Figure 4.5 Convergence analysis of WT PTEN 
!!
4.2.2.1 Root-mean-square deviation (RMSD) 
 The production phase of each simulation was monitored by checking the system 
temperature at 300 K which remained fairly constant throughout the simulations. The RMSD of 
the backbone was calculated with g_rmsd a module within the GROMACS program (see figure 
4.5A). 
 
4.2.2.2 Root-mean-square fluctuation (RMSF) 
 The fluctuation of the individual residues was calculated using g_rmsf a module within 
the GROMACS program (see figure 4.5B). 
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4.2.2.3 Radius of gyration (Rg) 
 The compactness of the overall protein was calculated using g_gyrate a module within 
the GROMACS program (see figure 4.5C). 
 
4.2.3 Protein structure network (PSN) communication pathway and 
community network analysis 
 Long-range communication and allosteric networks were characterized using a mixed 
protein structure network (PSN) and elastic network model-normal mode analysis (ENM-NMA) 
approach previously applied to investigate structural and allosteric communication 
pathways.236,237,323,324 Based on early work established by Vishveshwara et al.,234,235 the PSN is 
constructed from the atomic coordinates of residues, which represent the nodes of the network. 
Two nodes are connected by an edge if the percentage of the interaction between them is greater 
than or equal to a given Interaction Strength cut-off: 
 !!" = ! !!"!!"!!" 100                                 (Equation 4.1 Interaction Strength cut-off)     
                                                    
where Iij is the interaction percentage of nodes i and j, is the number of side-chain atom pairs 
within a given cut-off (4.5 Å), and Ni and Nj are, respectively, the normalization factors (NF) for 
residues i and j, which take into account the difference in size of different nodes and their 
propensity to make the maximum number of contacts with other nodes in protein structures. 
  The mixed PSN-ENM approach was recently implemented to predict salient structural 
communication pathway in biomolecular systems. The underpinning of WebPSN236 lies with a 
Protein Structure Graph (PSG) and searches for all shortest communication pathways between 
user-specified residues. A PSG defines amino acids as nodes and the non-covalent interactions 
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among them as links. Such graphs are useful in identifying clusters of residues that stabilize the 
protein structure and protein-protein interfaces.234 The network topology of PSGs depends on the 
cut-off of the interaction strength between residues used in the constructed graph.      
The mixed PSN-ENM method (WebPSN) involves a multi-step process where network 
features (i.e. nodes, hubs, links, etc.) are computed by building a PSG and the shortest 
communication pathways on ensembles of structures are acquired from a single high-resolution 
structure. The algorithm defines all possible communication paths between selected node pairs 
and filters the results to cross-correlation of atomic motions, as derived from ENM-NM. Filtering 
consists in retaining only the shortest path(s) that contains at least one residue correlated (i.e. with 
a cross-correlation value ≥0.6) with either one of the two extremes (i.e. the first and last residues 
in the path). Meta-paths made of the most recurrent nodes and links in the path pool (i.e. global 
meta-paths) and infer a coarse/global picture of the structural communication in the considered 
system. In detail, meta-paths are made of nodes ≥5% of the considered path pool (i.e. ‘frequent 
nodes’), and of links satisfying both conditions of being present in of the paths and of connecting 
‘frequent nodes’.  
 
4.2.4 Residue perturbation – local frustration analysis 
 A frustratometer algorithm was developed by the Wolynes and Komives group to 
determine residual local frustration that measures whether contact between residues is 
energetically optimized or not and evaluates how such changes affect the interaction energies.325 
Residues that are systematically destabilized by random changes in their vicinities are considered 
minimally frustrated, while those that are systemically stabilized are considered highly 
frustrated.325 To quantify local frustration in WT PTEN (PDB ID 1D5R), PTEN mutants, and 
PTEN-PIP3 complex, we utilized the frustratometer webserver326 
(http://frustratometer.qb.fcen.uba.ar) to assess the local frustration. For this work we utilized, 
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“mutational frustration” index, in which the decoy set involves randomizing the identities of the 
interacting amino acids, keeping all other interaction parameters at their native value. This 
scheme effectively evaluates every possible mutation of the amino acid pair that forms a 
particular contact in a robustly fixed structure. Minimally frustrated contacts in green and highly 
frustrated contacts in red are depicted of the contact on the structural models. The direct inter-
residue interactions are illustrated with solid lines and the water-mediated interactions with 
dashed lines. Projection of local frustration of the average frustration scores overall the contacts 
made by a particular residue are also plotted per-residue with the number of contact within 5 Å of 
the Cα of each residue. 
 
4.3 Results and discussion 
4.3.1 The effect of mutations on PTEN structure  
 To observe the dynamical behavior of residues, the RMSF value was calculated in the 
WT PTEN system from each Cα atom revealing dramatic fluctuation within the range of ~0.1-
0.58 nm in the n-terminal region and the WPD (residues 88-98) and P (residues 128-130) active-
site loops Figure 4.5B. The TI loop (residues 160-171) attained maximum level of fluctuation up 
to ~0.7 nm. To access the intra molecular compactness of the overall protein, the radius of 
gyration (Rg) was calculated over the lifetime of the simulation. There was an increase in the first 
50 ns and a subsequent decrease at ~128 ns prior to convergence (Figure 4.5C). Though these 
changes were minor and within a range of less than 0.15 nm, a closer inspection revealed the 
destruction of a critical salt-bridge involving catalytic residues R130 and D92. Further analysis 
revealed dramatic changes in the active-site loop conformation. Figure 4.6 illustrates the 
considerable deviation in the distance between R130 and D92. At 50 ns the distance between 
R130 NE2-D92 OD1 is 5.60 Å, however at 128 ns there is a disparate change in distance (12.37 
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Å). It appears that the WPD loop is initially in a “closed” conformation, strategically positioning 
the catalytically important aspartate residue closing over the active-site. However, the large 
conformational change destroys the R130-D92 salt-bridge moving the aspartate far out of the 
active-site representing an “open” conformation. 
 
Figure 4.6 Conformation change – “closed” to  “open” 
 
 
4.3.2 Inter-domain communication pathway 
4.3.2.1 Inter-domain meta-path analysis 
To specifically identify a relevant path of communication within the structure of each 
PTEN system, a mixed protein structure network (PSN) and elastic network model (ENM) 
approach was employed.236,237,323,324 The building of the protein structure graph (PSG) was carried 
!!107 
out by means of the PSN algorithm. The strength of interaction between residues i and j (Iij) was 
evaluated as a percentage, then Iij was calculated for all node pairs. The interaction strength, Imin 
was chosen and any residue pair for which Iij ≥ Imin is considered to be interacting and hence 
connected to the PSG. The network components and parameters for each system are outlined in 
Table 4.2.  
 
Table 4.2 Network components and parameters 
 PTEN 
(apo) 
PTEN-
PIP3 
R130G R130L R130Q R173C R173H 
Imin 3.36 3.97 4.11 3.51 3.38 3.89 3.5 
Hubs 35 37 26 36 50 28 30 
Links 226 219 166 217 255 193 221 
Paths 11302 26609 12015 15267 37935 14092 18434 
Nodes 193 189 139 185 193 168 179 
 
 In a previous study, we calculated anisotropic network analysis (ANM) and all-atom 
principal component analysis (PCA) of atomic fluctuations which highlighted “hinge-bending” 
and “zipper-like” PTEN motions as well as the dynamic fingerprint and displacement of the 
active-site loops, CBR3 loop, and inter-domain interface,300 to which these inferences lend their 
support in ascertaining the underlying structural communication pathway of PTEN. The PTEN 
mutations, PTEN-PIP3 substrate interactions as well as conformational dynamics, all exert 
differential impacts on structural communication. The latter can be examined by representing 
PTEN structures as an elastic network of interacting residues. PSN analysis was utilized to 
deduce the effects mutations have on the native fingerprint and stable residues within the 
structure network. 
 !  
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4.3.2.1.1 Meta-path analysis of WT PTEN 
Figure 4.7 Meta-path analysis 
 
 
A detailed comparison of the communication paths in PTEN allows us to identify distinct 
long-range salient communication pathways. Figure 4.7 highlights the meta-path, of each PTEN 
system, which contains regions that participate in the stability of the protein core (inter-domain) 
in the overall dynamics of the protein. Our results reveal that though the WT PTEN (apo) has an 
identifiable communication pathway that is more spread out over the N-terminal region of the 
protein structure, it’s strongest interaction is within the inter-domain interface (Figure 4.7A). The 
PTEN-PIP3 complex has an even more distinguishable pathway that illustrates the strongest 
interaction to be in the WPD loop (residues 88-98) of the active-site that moves into the core of 
the protein and spreading throughout the C2 domain (Figure 4.7B). Interestingly, as expected, 
upon ligand binding the phosphatase domain acquires hubs in the active-site as well as inter-
domain region.  
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4.3.2.1.2 Meta-path of cancer-associated PTEN mutants 
The remaining meta-paths involving the PTEN mutants captured a rather significant 
scheme in their pathways of communication. Each of the mutants had the active-site loops 
involved in their pathways most particularly the WPD loop (residues 88-98) which contains the 
acidic/basic D92 that participates in catalysis. They share several other features that consist of 
residues in their hubs containing both ATP-binding sites (residues 60-73 and 122-136) in addition 
to the CBR3 loop (residues 260-269). However, PTENR130Q has only a few active-site hubs in its 
pathway (Figure 4.7G).  It is known that various misfolding mutations tend to impair selective 
native stable hubs; the extent to which this structural effect appears is related to the extent of the 
biochemical defect associated with the mutation.234 Interestingly, PTENR130G demonstrates a more 
clustered pathway concentrated in its core that affects the compactness of the protein structure 
(Figure 4.7E). A recent study revealed that PTENR130G mutant alters the polarity and charge of 
the active-site leading to a structurally instable and catalytically inactive mutant.327 Consistent 
with the catalytically active mutants PTENR130L, PTENR130Q, PTENR173C, and PTENR173C, the 
number of hubs in the WT PTEN (apo) and PTEN-PIP3 complex systems were higher than the 
catalytically inactive PTENR130G which had lowest number of hubs as seen in Table 4.2 and 
Figure 4.7. 
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Figure 4.8 Nodes, hubs, and links 
 
 
This further emphasizes the role of the highly conserved R130 position both in structural 
stability, and intra-protein allosteric communication, as it is an integral hub residue participating 
in both inactive and active states. The PTENR130Q mutant is richer overall in hubs, links, and 
nodes. Moreover, its communication pathway obtained highly enriched hubs within inter-domain 
region as well as the CBR3 loop (residue 260-269) (Figure 4.7G). Similarly, PTENR130Q 
demonstrated the greatest frequency of nodes (percentage) overall in the whole pool of paths 
(Figure 4.9). The PTEN-PIP3 complex was third overall with the highest hubs, links and nodes; 
yet it revealed the most distinctive inter-domain communication pathway. Though the R173 
mutant systems didn’t reveal a distinct communication pathway, they had the fewest hubs second 
only to PTENR130G (Table 4.2 and Figure 4.8). This can be attributed to the mutation being in the 
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central core of the protein; therefore decreasing normal interactions required for their 
communication network.  
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Figure 4.9 Frequency of nodes in the whole pool paths 
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Several active-site residues, ATP-binding site resides and CBR3 loop residues were 
found to participate in the frequency of nodes of all systems in the whole pool of paths that 
played a critical role in the salient communication pathway (Figure 4.9). In comparing the WT 
PTEN (apo) system with the mutants, the WT demonstrated several residues that had a high 
frequency of nodes within its pool of paths. Most particularly, the residues belonged in the CBR3 
loop (residues W261, F266, and I267), TI loop (residues Y161 and Y164), WPD loop (F91, L95, 
and W98), ATP-binding site (H62, Y63, and F68), and the critical and highly conserved R130 
residue (with 60% frequency) in the central node of the active-site. 
PTENR130G only had a few residues that belong to the active-site as part of the frequency 
of nodes within its pool of paths such as the WPD loop (residues F90, N93, P95, and Q97), P 
loop (residues T131, M134, and I135) and the conserved R173 residue (with 50% frequency) 
location within the inter-domain interface. PTENR130L only had residues in the WPD loop 
(residues F90, E91, N94, Q97, and L98) appear in its pool of paths. Interestingly, Q97 had a 
frequency of 75%, which is adjacent to the acidic D92 that interacts with R130 in catalysis. 
Additionally, W274 appears with a 65% frequency, which is a rather significant as this residue 
participates in hydrogen bonding with R173 within the rich hydrogen-bond network of the inter-
domain interface. In the R173C/H mutations, steric clash is imposed and side chain distortion 
occurs abolishing the W274 and R173 hydrogen-bond interaction.  Similarly, PTENR130Q only had 
a few residues of interest that belong to the CBR3 loop (residues K267 and K269) and one of the 
ATP-binding sites (residues K66 and Y68). Of relevance is the residue Q97 that also appears in 
R130Q mutation pool with a 75% frequency. PTENR173C also had a small number of residues 
within the active-site, WPD loop (residues Y88, F90, N94, and Q97), and residues in an ATP-
binding site (N63, Y65, K66, and I67) as part of its pool. Of importance was the appearance of 
W274 and D92 in this pool with a frequency of 65% and 68%, respectively. Lastly, PTENR173H 
comprised of several residues in the active-site appear in its frequency of nodes pool of paths. 
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Specifically, the CBR3 loop (residues K260, K267, K269, and F271), P loop (residues H123 and 
R130), WPD loop (residues Y88, F90, P95, and P96), and an ATP-binding site (residues Y68 and 
C71), with R130 and W274 appearing at a frequency of 45% and 58%. These residues all play a 
critical role in the salient communication pathway as outlined for each of the systems.  
 
4.3.3 Community network analysis 
 A set of seven independent all-atom molecular dynamics (MD) simulations were 
conducted for wild-type PTEN (apo), PTEN-PIP3 complex, and PTENR130G, PTENR130L, 
PTENR130Q, PTENR173C and PTENR173H mutants. During the WT PTEN (apo) simulation, a rather 
large conformational change occurred within the active-site involving the P loop (residues 123-
130), WPD loop (residues 88-98) and TI loops (residues 160-171) forming a more “open” active-
site. A closer inspection revealed the destruction of a critical salt-bridge involving residues R130 
and D92.  The positioning of these two residues is essential for their interaction with the PIP3 
substrate and the overall function of PTEN. Further investigation of each of the remaining 
systems, revealed considerable changes in the active-site loop conformations. Moreover, our 
recent structure and global dynamics studies revealed inter-domain communication caused by 
mutations at positions 130 and 173 that lead to a dramatic effect on PTEN long-range 
communication within the protein. This motived a more thorough understanding of 
communication pathways to further elucidate the functional effect each mutation has in the 
development of endometriosis, endometrial and ovarian cancers. 
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Figure 4.10— Conformational analysis of active-site loops 
 
 
4.3.3.1 Community analysis of WT PTEN 
 A community network analysis approach236,237,323,324 was applied to identify regions 
(‘communities’) within the protein that are closely correlate within the selected systems: WT 
PTEN (apo), PTEN-PIP3 complex and PTENR130G, PTENR130L, PTENR130Q, PTENR173C, and 
PTENR173H mutants. These communities are correlated with each other through key residues that 
establish contacts for long-range allosteric mechanisms.328 Representative communication 
network analyses obtained from the simulations are shown in Figure 4.11. Communities are sets 
of highly interconnected vertices such that nodes belonging to the same community are densely 
linked to each other and poorly connected to nodes outside the community.324 The protein 
network is divided into communities based on the flow of allosteric information that passes 
through each pair of nodes (‘edge). This is defined as the number of shortest pathways that pass 
through the edge and is measured by the edge betweenness parameter. 
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Figure 4.11 Community network analysis 
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Our results reveal that each of the mutants displayed dissociation between both halves of their 
domains, more specifically within their inter-domain regions where as WT PTEN (apo) and 
PTEN-PIP3 behave more as individual communities. Both of their domains appear as distinct 
though strongly connected communities. This is consistent with PTEN’s functional nature of 
substrate binding and catalysis. The community connections within the active-site and inter-
domain regions of the WT (apo) and PTEN-PIP3 complex, highlights the effectiveness of the 
substrate-binding contacts are which allows for communication between the two domains. As 
indicated by the sizeable connectivity of communities within the inter-domain region of the apo 
and PTEN-PIP3 complex, further confirms that the rich hydrogen-bond network within the inter-
domain interface allows information to pass through inter-domain interface. 
 
4.3.3.2 Community analysis of cancer-associated PTEN mutants 
 PTENR173C had the most dissimilar communities possibly indicative of the loss of long-
range communication pathway as a result of the mutation. Interestingly, PTENR130Q exhibited a 
rather strongly connected community within the inter-domain interface. This is suggestive of 
these regions making a rather dense network possibly involved in the overall structural stability of 
the protein. The small number of communities in PTENR130G as well as the lack of distinct 
communities and display of weak communications throughout the protein is most likely is due to 
the complete abolishment of charge as a result of the mutation. Charged or polar long-chain 
residues appear to be fundamental in transmitting allosteric information across different subunits. 
Similarly PTENR130L and PTENR173H had very few distinct communities except for some distinct 
communities within the CBR3 loop (residues 260-269) region indicating the significance of this 
region in transmitting information across the protein structure network. 
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4.3.4 Residual perturbation – local frustration analysis 
 To quantify the local frustration, we applied a frustratometer algorithm325,326 to RMSD 
clusters of representative structures from each system. Residual Local Frustration is a measure of 
how ‘frustrated’ a residue is by verifying local/regional mutational or conformational changes 
shift residue energetics.325 According to the principal of minimal frustration, which has its basis 
in the energy landscape theory, though minimally frustrated contacts (energetically favorable) are 
critical to stabilize the core of the protein, local clusters of highly frustrated contacts 
(energetically unfavorable) may have evolved facilitating protein motion and to allow the protein 
to modulate their function in response to their environment.325 These highly frustrated contacts 
are thought to have profound effects on structural transitions and map to functional sites of the 
protein. 
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Figure 4.12 Residual frustration analysis 
 
 
4.3.4.1 Residual frustration analysis of WT PTEN 
Figure 4.12 demonstrates the distribution of minimally (green) and highly (red) 
frustrated contacts within the active-site as well as the inter-domain interface of each of the 
investigated systems. The highly frustrated clusters most likely map to the active-site and inter-
domain regions as a result of the interdependent conformational changes that must occur in 
protein-protein interactions or when interacting with the PIP3 substrate. Since these regions are 
also conserved across multiple phosphatases, it highlights that regions of high-residual frustration 
may reflect an evolutionary requirement that often corresponds to functionally relevant sites.325 
Moreover, the conserved structural elements in the active-site, are coordinated by specific 
electrostatic interactions in order to achieve the precise positioning required for function. With 
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the domain-interface positioned adjacent to the active-site, its destabilization may be as a result of 
the increased stability of active-site substrate interactions as seen in Figure 4.12B.  
 
4.3.4.2 Residual frustration analysis of cancer-associated PTEN mutants 
Interestingly, the R130G/L/Q mutant systems encompass more frustrated contacts within 
the lower region of the adjoining inter-domain interface than other systems, more specifically the 
R173C/H mutations, which are located within the inter-domain interface. Moreover, the 
frustration index for each system as shown in Figure 4.13, illustrates three key areas that appear 
highly frustrated to varying degree in areas across the domains compared to the remainder of the 
protein. These regions encompass an area (residues 80-100) contiguous to the active-site, an 
ATP-binding motif, the inter-domain interface, and the CBR3 loop (residues 260-269). These 
results are in agreement with our previous studies where these mutated positions exhibited an 
increase in dynamics across the phosphatase-C2 domain interface further demonstrating that the 
integrity of this region is crucial to the overall structural stability of PTEN.  
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Figure 4.13 Frustration index  
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This index demonstrates how favorable a particular contact is relative to the set of all 
possible contacts in that location normalized utilizing the variance of that distribution.325 A 
contact is defined as ‘minimally frustrated’ (green) if its native energy is at the lower end of 
distribution, having a frustration index of 0.78 or higher, indicating that other residues in that 
position would be unfavorable. Conversely, a contact is defined as ‘highly frustrated’ (red) if the 
native energy is at the other end of the distribution with a local frustration lower than -1, 
indicating that most other residues at that location would be favorable for folding than the native 
ones at standard deviation of distribution. If the native energy is between these two values, the 
contact is defined at ‘neutral’ (grey or not depicted). Interestingly, the PTEN-PIP3 complex 
demonstrated a higher frustration index in the CBR3 loop region, illustrating that the binding of 
PIP3 extends interdependent motions potentially corroborating a communication pathway 
essential to its catalytic function. 
 
4.4 Conclusions 
We utilized a combination of community network analysis, all-atom molecular dynamic 
simulations, and analysis of residual frustration to explore the dynamic ensemble of PTEN. 
Comparative analysis of WT PTEN (apo), PTEN-PIP3 complex and PTENR130G, PTENR130L, 
PTENR130Q, PTENR173C, and PTENR173H mutant systems identified difference in the long-range 
communication pathway as a result of ligand bound in active-site or mutation. Community 
analysis of PTEN mutants revealed community dissociation between both halves of their 
domains, more specifically within their inter-domain regions, whereas WT PTEN (apo) and 
PTEN in complex with PIP3 revealed a more strongly connected community structure with 
convergence within the inter-domain interface (Figure 4.11). 
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The analysis of residual local frustration revealed that the R130G/L/Q mutant systems 
encompass more frustrated contacts within the lower region of the adjoining inter-domain 
interface than other systems, more specifically the R173C/H mutations, which are located within 
the inter-domain interface (Figure 4.12). Moreover, the frustration index illustrates three key 
areas that appear highly frustrated to varying degree in areas across the domains compared to the 
remainder of the protein (Figure 4.13). Interestingly, the PTEN-PIP3 complex demonstrated a 
higher frustration index in the CBR3 loop region, illustrating that the binding of PIP3 extends 
interdependent motions potentially corroborating a communication pathway essential to its 
catalytic function. However, in the case of the apo mutant systems, there exists a potential salient 
communication pathway underscoring a possible mutation-driven allosteric inter-domain 
interface.  Interestingly, some flexible regions are separated by minimally frustrated contacts at 
the core of the protein; therefore it is crucial to investigate how information is transmitted along 
the structure through interdependent motions. 
Our meta-path analysis revealed that though the WT PTEN (apo) has an identifiable 
communication pathway that is more spread out over the N-terminal region of the protein 
structure, it’s strongest interaction is within the inter-domain interface (Figure 4.7A). The PTEN-
PIP3 complex has an even more distinguishable pathway that illustrates the strongest interaction 
to be in the WPD loop (residues 88-98) of the active-site that moves into the core of the protein 
and spreading throughout the C2 domain (Figure 4.7B). Notably, the meta-paths involving the 
PTEN mutants captured a rather significant scheme in their pathways of communication. Each of 
the mutants, had the active-site loops involved in their pathways and share several other features 
that consist of residues in their hubs containing both ATP-binding sites (residues 60-73 and 122-
136) in addition to the CBR3 loop (residues 260-269). However, PTENR130Q only had a few 
active-site hubs in its pathway (Figure 4.7G). The numbers of hubs in the WT PTEN (apo) and 
PTEN-PIP3 complex systems were higher than the known catalytically inactive PTENR130G, which 
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had lowest number of hubs (Table 4.2 and Figure 4.8), this was consistent with the catalytically 
active mutants PTENR130L, PTENR130Q, PTENR173C, and PTENR173C.  
These results further emphasize the role of the highly conserved R130 position both in 
structural stability, and intra-protein allosteric communication, deeming it as an integral hub 
residue participating in both inactive and active states. Interestingly, the semi-closed 
conformations represented in the PTENR130L, PTENR173C, and PTENR173C mutants feature peculiar 
properties (a modest decrease in long-range paths) enforcing the notion that the global 
conformational changes between open and closed conformations is accompanied by internal 
alterations of the dynamical properties (Figures 4.7 and 4.10). Moreover, allosteric pathways 
typically involve highly frustrated clustered and specific polar amino acid residues such as R130 
and R173. Overall our results demonstrate how all-atom MD, combined with PSN-ENM-NMA, 
and analysis of residual local frustration can be utilized to infer salient communication pathways 
in PTEN and suggest potential mechanisms for the coupling between the effects missense 
mutations have on global dynamics, structural communication, and function of PTEN.  Future 
experiments might involve the characterization supporting the reported results that could 
potentially lead to new strategies in the development of allosteric drugs that target the inter-
domain region of PTEN. 
 
 
 
 
 !  
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Chapter 5: Future directions 
5.1 Chapter 3 future directions 
Our study comprises an in silico effort in examining 13 somatic missense mutations in 
PTEN associated with endometriosis, endometrial cancer, and ovarian cancer. A combination of 
methods based on assessing protein structure stability, sequence evolutionary information, 
electrostatic potential, and protein global dynamics were employed to gain insight into the 
mutational effects that drive phenotypic outcome. Our observed predictions correlated with a 
decrease in protein structure stability in each of the associated mutations. I-Mutant 3.0 predicts all 
13 mutations to be destabilizing. ENCoM predicts 6 mutations, (p.R130G/L/Q, p.R173C/H, and 
p.V191A) to be destabilizing. The effect of these mutations on structural stability and dynamics 
were further assessed indicating that the p.R130G/L/Q and p.R173C/H mutants have an increase 
in dynamics across the phosphatase-C2 domain interface.  
Moreover, our results indicate that mutations at positions 130 and 173 may trigger certain 
types of allosteric changes as well as long-range communication effects that contribute to the loss 
of phosphatase activity toward PIP3, thus giving rise to a severe phenotype. The results of our 
study can be exploited for future mutagenesis studies and as a framework to predict PTEN 
mutation severity beyond existing algorithms. Due to the potential significance of positions R130 
and R173 being mutation-driven allosteric sites, the mechanism for their rescue of destabilized 
mutants, if not by global contribution to structure stability alone, poses a crucial question. 
Therefore, further analysis of the catalytic as well as tumor suppressor functions of mutations at 
positions 130 and 173 will aid in understanding the significance of mutational targeting of these 
positions in various cancers. A corresponding double mutant, at positions 130 and 173 will offer 
insight as to whether a rescue mutant confers potential contribution to structural stability (ΔΔG). 
Of particular significance, is that the active-site also encompasses an ATP-binding motif 
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(residues 122-136) that modulates PTEN’s subcellular localization. Cancer-associated mutations 
that lie within this ATP-binding motif, result in mutant PTEN that does not bind ATP resulting in 
altered signaling and growth; therefore underlying its critical pathogenic role in both heritable 
and sporadic carcinogenesis by PTEN nuclear mislocalization. In assessing the structural 
stability, change in charge, and global dynamics of PTEN ATP-binding motif mutations 
contained within this study such as p.R123Y, p.C124S, p. G129E/R, and  p.R130G/L/Q 
mutations, represent an added advantage in understanding how the disruption of binding ATP 
results in endometriosis and cancer-associated phenotypes and present novel therapeutics in 
tumors with such PTEN alterations. 
Additionally, our results provide a platform to further assess experimentally the effects of 
the mutations on stability of the inter-domain interface. To exploit this approach from an 
experimental standpoint, NMR could be utilized to determine the increase of flexibility of the 
inter-domain interface due to p.R173C and p.R173H mutations. Furthermore, shifts in pKa and 
hydrogen bond rearrangement at p.R130 mutations could also be tested by means of NMR along 
with thermal or denaturant unfolding methods.!
 
5.2 Chapter 4 future directions 
 Our results encompass the combination of all-atom MD, combined with PSN-ENM-
NMA, and analysis of residual local frustration to infer salient communication pathways in PTEN 
and suggest potential mechanisms for the coupling between the effects missense mutations have 
on global dynamics, structural communication, and function of PTEN. This combined approach 
allowed us to analyze the long-range communication within PTEN and associated mutants of the 
endometriosis, endometrial, and ovarian cancer phenotypes. Our choice of in silico generated 
mutants (R130G, R130L, R130Q, R173C, and R173H), derives from the high frequency 
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association of endometriosis and cancer at positions 130 and 173 (Figure 4.1) with each of the 
aforementioned phenotypes as well as our previous structural studies of PTEN.300 
We identified distinct differences in the long-range communication pathway as a result of 
ligand bound in active-site (PTEN-PIP3) or a mutation within the R130 and R173 positions. 
Comparative community analysis of PTEN mutants revealed community dissociation between 
both halves of their domains, more specifically within their inter-domain regions, whereas WT 
PTEN (apo) and PTEN in complex with PIP3 revealed a more strongly connected community 
structure across the inter-domain interface (Figure 4.11). This demonstrates that the long-range 
communication is disrupted due to a mutational effect within the active-site or inter-domain 
region. Interestingly, the PTEN-PIP3 complex demonstrated both a higher residual local 
frustration and frustration index in the CBR3 loop region, illustrating that the binding of PIP3 
extends interdependent motions potentially corroborating a communication pathway essential to 
its catalytic function. The meta-path analysis revealed that the WT PTEN (apo) had an 
identifiable communication with its strongest interaction within the inter-domain interface 
(Figure 4.7A). The PTEN-PIP3 complex had an even more distinguishable pathway that 
illustrates the strongest interaction to be in the WPD loop (residues 88-98) that propagated 
throughout the C2 domain (Figure 4.7B). In particular, the PTEN mutants captured a rather 
significant scheme in their pathways of communication, which involved the active-site loops as a 
significant hub within their pathways. 
Further analysis of the analyzed PTEN mutants coupled with either the PIP3 substrate or 
ATP would provide further insight into the salient communication pathway for each of the 
aforementioned phenotypes as well as other cancer-associated mutations in the active-site and 
ATP-binding motif. Additionally, a comprehensive statistical coupling analysis on the co-
evolution of R130 and R173 mutants could reveal potential new allosteric drug target sites in 
cancer therapy. These positions both reside in highly conserved regions of PTEN’s structure. 
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Since a protein’s function is dependent on it’s three-dimensional structure as well as interaction 
of residues and their influence on structural stability, it is therefore essential to understand how 
compensatory mutations may occur to preserve or restore the function or structure of PTEN. In 
order to quantify evolutionary conserved network pathways that mediate allosteric 
communication and the co-variation between the two sites (R130 and R173), a mutual 
information (MI) model can be utilized.329 There are many computational MI methods to exploit, 
however MI based on the incorporation and measurement of the residue background distribution 
as well as the measurement of individual residue physiochemical properties of two sites is critical 
to obtaining effective evaluation.330 The R130 and R173 residues can in turn be exploited to 
further stabilize PTEN’s structure and overall function in developing novel therapeutics in the 
treatment of cancer-associated PTEN mutants. 
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